インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
8. 進行中の試験（延長パートを含む）における曝露期間

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.8.1 Exposure time from extension trials and ongoing trials - summary - safety analysis set.....2
7.8.2 Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set 3
7.8.3 Adverse events with special focus areas (MedDRA search) - summary - ongoing extension trials 8
7.8.4 Adverse events with special focus areas (MedDRA search) - summary - ongoing IcoSema trials.....8

7.8 Exposure time from extension trials and ongoing trials

7.8.1 Exposure time from extension trials and ongoing trials - summary - safety analysis set

	Total	
	N	(PYE)
NN1436-4477 (ONWARDS 1, extension)	984	(492.87)
NN1436-4625 (ONWARDS 6, extension)	582	(340.76)
NN1436 total	1566	(833.63)
NN1535-4591	408	(51.84)
NN1535-4592	450	(85.34)
NN1535-4593	582	(188.54)
NN1535-4710	2	(0.22)
NN1535 total	1442	(325.94)

N: Number of subjects, PYE: Patient years of exposure (1 PYE = 365.25 days). Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

7.8.2 Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set

Subject ID/ Trial ID	AE no.	System organ class/ Preferred term/ Reported term	Onset date/ End date/ Duration (days)	Outcome	Seriousness/ Severity/	MedDRA version
405013/ NN1436-4477	5	Gastrointestinal disorders/ Abdominal distension/ Bloating	02JUL2022/ /	Not recovered/not resolved	Non-serious/ Mild	24.1
	6	Gastrointestinal disorders/ Constipation/ Constipation	02JUL2022/ /	Not recovered/not resolved	Non-serious/ Mild	24.1
501019/ NN1436-4477	8	Metabolism and nutrition disorders/ Hypoglycaemia/ Hypoglycamia	12JUL2022/ 04AUG2022/ 24	Recovered/resolved	Serious/ Severe	24.1
708003/ NN1436-4477	4	Psychiatric disorders/ Psychotic disorder/ Acute psychotic episode	20JUN2022/ 28JUN2022/ 9	Recovered/resolved	Serious/ Severe	24.1
163003/ NN1535-4591	2	Gastrointestinal disorders/ Nausea/ Nausea	16AUG2022/ 24AUG2022/ 9	Recovered/resolved	Non-serious/ Moderate	25.1
	3	Gastrointestinal disorders/ Abdominal pain/ Abdominal pain	16AUG2022/ 24AUG2022/ 9	Recovered/resolved	Non-serious/ Moderate	25.1

AE no.: Adverse event number. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set

Subject ID/ Trial ID	AE no.	System organ class/ Preferred term/ Reported term	Onset date/ End date/ Duration (days)	Outcome	Seriousness/ Severity/	MedDRA version
408002/ NN1535-4591	1	Gastrointestinal disorders/ Nausea/ Nausea	02AUG2022/ 10AUG2022/ 9	Recovered/resolved	Non-serious/ Moderate	25.1
137003/ NN1535-4592	1	Gastrointestinal disorders/ Oral mucosal erythema/ Inflamed oral mucous membranes	08JUN2022/ 05JUL2022/ 28	Recovered/resolved	Non-serious/ Moderate	25.1
154002/ NN1535-4592	1	Injury, poisoning and procedural complications/ Tendon injury/ Tricep tear, right	01AUG2022/ 02AUG2022/ 2	Recovered/resolved	Non-serious/ Moderate	25.1
101006/ NN1535-4593	1	Immune system disorders/ Hypersensitivity/ Hypersensitivity reaction	05SEP2022/ 09SEP2022/ 5	Recovered/resolved	Non-serious/ Mild	25.1
151003/ NN1535-4593	3	Gastrointestinal disorders/ Diarrhoea/ Diarrhea	11JUL2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1

AE no.: Adverse event number. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set

Subject ID/ Trial ID	AE no.	System organ class/ Preferred term/ Reported term	Onset date/ End date/ Duration (days)	Outcome	Seriousness/ Severity/	MedDRA version
155001/ NN1535-4593	2	Nervous system disorders/ Cerebrovascular accident/ Stroke	22JUL2022/ 26JUL2022/ 5	Recovered/resolved	Serious/ Moderate	25.1
251003/ NN1535-4593	5	Gastrointestinal disorders/ Abdominal pain upper/ Stomach ache	09AUG2022/ 14AUG2022/ 6	Recovered/resolved	Non-serious/ Moderate	25.1
	7	Gastrointestinal disorders/ Diarrhoea/ Diarrhea	09AUG2022/ 14SEP2022/ 37	Recovered/resolved	Non-serious/ Moderate	25.1
403007/ NN1535-4593	22	Metabolism and nutrition disorders/ Hypoglycaemia/ Hypoglycemia	06SEP2022/ 06SEP2022/ 1	Recovered/resolved	Non-serious/ Mild	25.1
553002/ NN1535-4593	1	Gastrointestinal disorders/ Nausea/ Nausea	11AUG2022/ 16AUG2022/ 6	Recovered/resolved	Non-serious/ Severe	25.1

AE no.: Adverse event number. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set

Subject ID/ Trial ID	AE no.	System organ class/ Preferred term/ Reported term	Onset date/ End date/ Duration (days)	Outcome	Seriousness/ Severity/	MedDRA version
703007/ NN1535-4593	1	Skin and subcutaneous tissue disorders/ Rash/ Generalized systemic rash	08JUL2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1
	2	Gastrointestinal disorders/ Vomiting projectile/ Projectile vomitting	09JUL2022/ 09JUL2022/ 1	Recovered/resolved	Non-serious/ Moderate	25.1
	3	Gastrointestinal disorders/ Nausea/ Worsening nausea	08JUL2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1
	4	Gastrointestinal disorders/ Diarrhoea/ Diarrhea	10JUL2022/ 11JUL2022/ 2	Recovered/resolved	Non-serious/ Moderate	25.1
	5	General disorders and administration site conditions/ Fatigue/ Fatigue	08JUL2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1
	6	Nervous system disorders/ Neuropathy peripheral/ Worsening neuropathy	08JUL2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1
707005/ NN1535-4593	3	Psychiatric disorders/ Depression/ Depression	25JUL2022/ 09AUG2022/ 16	Recovered/resolved	Non-serious/ Moderate	25.1
	4	Psychiatric disorders/ Irritability/ Irritability	25JUL2022/ 09AUG2022/ 16	Recovered/resolved	Non-serious/ Moderate	25.1

AE no.: Adverse event number. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

Adverse events leading to permanent discontinuation of trial product in extension trials and ongoing trials - listing - safety analysis set

Subject ID/ Trial ID	AE no.	System organ class/ Preferred term/ Reported term	Onset date/ End date/ Duration (days)	Outcome	Seriousness/ Severity/	MedDRA version
714003/ NN1535-4593	7	Metabolism and nutrition disorders/ Hyperglycaemia/ Worsening hyperglycemia	14JUN2022/ /	Not recovered/not resolved	Non-serious/ Moderate	25.1
733004/ NN1535-4593	1	Gastrointestinal disorders/ Vomiting/ Vomiting	02AUG2022/ 18AUG2022/ 17	Recovered/resolved	Non-serious/ Moderate	25.1
	4	Gastrointestinal disorders/ Abdominal pain/ Abd cramps	02AUG2022/ 18AUG2022/ 17	Recovered/resolved	Non-serious/ Mild	25.1

AE no.: Adverse event number. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5).

7.8.3 Adverse events with special focus areas (MedDRA search) - summary - ongoing extension trials

	N	E
Hyperglycaemia incl. diabetic ketoacidosis	5	5
Other microvascular diabetic complications (peripheral vascular disease and renal impairment)	5	5
Diabetic retinopathy or maculopathy	47	57
Clinically meaningful peripheral oedema	18	19
Hypokalaemia	0	0
Neoplasms	22	23
Lipodystrophy	1	1
Localised amyloidosis	0	0

N: Number of subjects with one or more events, E: Number of adverse events. Data from ONWARDS 1 and 6 includes extension part until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5). MedDRA version 24.1.

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:56:42 - taesfaextension/taesfaextension.txt

7.8.4 Adverse events with special focus areas (MedDRA search) - summary - ongoing IcoSema trials

	N	E
Hyperglycaemia incl. diabetic ketoacidosis	17	18
Other microvascular diabetic complications (peripheral vascular disease and renal impairment)	0	0
Diabetic retinopathy or maculopathy	11	11
Clinically meaningful peripheral oedema	7	7
Hypokalaemia	0	0
Neoplasms	10	12
Lipodystrophy	1	1
Localised amyloidosis	0	0

N: Number of subjects with one or more events, E: Number of adverse events. Data from NN1535-4591, NN1535-4592, NN1535-4593 until cut-off date. Cut-off date: 19-Sep-2022 (database lock date for ONWARDS 5). MedDRA version 25.1.

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:15:36:29 - taesfaongoing/taesfaongoing.txt

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
9. 有害事象の叙述の一覧

ノボ ノルディスク ファーマ株式会社

Common Technical Document Summaries

Insulin icodec

2.7.4: Appendix 7.9

List of narratives

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Table of contents

Page

Table of contents **2**

List of abbreviations and definitions of terms **3**

1 Background and methods **4**

2 Narratives for deaths (adverse events with fatal outcome) **5**

3 Narratives for phase 3a pool **7**

3.1 Hypoglycaemia – serious adverse events 7
3.2 Neoplasms 7
3.2.1 Neoplasms - serious adverse events – in-trial 7
3.2.2 Neoplasms - non-serious adverse events – in-trial 9
3.3 Diabetic retinopathy or maculopathy 12
3.3.1 Diabetic retinopathy or maculopathy - serious adverse events – in-trial 12
3.3.2 Diabetic retinopathy or maculopathy - non-serious adverse events – in-trial 13
3.4 Hyperglycaemia incl. diabetic ketoacidosis 21
3.4.1 Hyperglycaemia incl. diabetic ketoacidosis - serious adverse events – in-trial 21
3.4.2 Hyperglycaemia incl. diabetic ketoacidosis - non-serious adverse events – on-treatment 22
3.5 Hypokalaemia 23
3.5.1 Hypokalaemia - serious adverse events – in-trial 23
3.5.2 Hypokalaemia - non-serious adverse events – on-treatment 23
3.6 Other microvascular diabetic complications 23
3.6.1 Other microvascular diabetic complications - serious adverse events – in-trial 23
3.6.2 Other microvascular diabetic complications - non-serious adverse events – in-trial 23
3.7 Clinically meaningful peripheral oedema 25
3.7.1 Clinically meaningful peripheral oedema - serious adverse events – in-trial 25
3.7.2 Clinically meaningful peripheral oedema - non-serious adverse events – on-treatment 25
3.8 Lipodystrophy 26
3.8.1 Lipodystrophy - serious adverse events – in-trial 26
3.8.2 Lipodystrophy - non-serious adverse events – in-trial 26
3.9 Localised amyloidosis 26
3.9.1 Localised amyloidosis - serious adverse events – in-trial 26
3.9.2 Localised amyloidosis - non-serious adverse events – in-trial 26
3.10 Injection site reaction – serious adverse events 26
3.11 Hypersensitivity - serious adverse events 27
3.12 Immunogenicity - serious adverse events 27
3.13 Rare event – serious adverse events 27
3.14 Suspected transmission of infectious agents – serious adverse events 28
3.15 Medication error including misuse and abuse – serious adverse events 28
3.16 Serious adverse events not covered by safety focus areas 29
3.17 Non-serious adverse events leading to treatment discontinuation 38

4 Narratives for phase 2 trials **39**

4.1 Trial NN1436-4383: 39
4.2 Trial NN1436-4465 39
4.3 Trial NN1436-4466 39

5 Narratives for clinical pharmacology trials **41**

6 Narratives for pregnancies **42**

List of abbreviations and definitions of terms

AE	adverse event
COVID-19	coronavirus disease 2019
CTR	clinical trial report
MedDRA	Medical Dictionary for Regulatory Activities
NN	Novo Nordisk
OD	once-daily
SAE	serious adverse event
SUSAR	suspected unexpected serious adverse reaction

1 Background and methods

For the phase 3a trials, case narratives were to be provided for:

- Deaths
- SAEs
- Pregnancies
- Non-serious AEs leading to permanent discontinuation of trial product
- Non-serious AEs within the following focus areas (for details about the MedDRA search criteria, please refer to Appendix 7.10):
  - Neoplasm
  - Diabetic retinopathy or maculopathy
  - Hyperglycaemia including diabetic ketoacidosis
  - Hypokalaemia
  - Other microvascular diabetic complications
  - Clinical meaningful peripheral oedema
  - Lipodystrophy
  - Localised amyloidosis

For the phase 2 trials and the clinical pharmacology trials, case narratives were to be provided for:

- Deaths (no cases)
- Other SAEs
- Pregnancies (no cases)
- Non-serious AEs leading to permanent discontinuation of trial product

(*some CTRs contain more narratives than those listed above, if relevant for the trial*)

All case narratives are located in Section 14.3.3 of the individual CTRs. To ease navigation, this appendix provides a list of selected narratives with hyperlinks to the individual narratives in the CTRs.

2 Narratives for deaths (adverse events with fatal outcome)

Unique subject ID	Case Number	Reason(s) for Narrative	Preferred Term	Actual treatment
ONWARDS 1				
NN1436-4477/106008	844133	SAE Death AE leading to permanent discontinuation of trial product	COVID-19	Insulin icodec
NN1436-4477/406001	864478	SAE Death	Post procedural infection	Insulin glargine
NN1436-4477/406001	864478	SAE Death AE leading to permanent discontinuation of trial product	Angina pectoris	Insulin glargine
NN1436-4477/455002	852745	SAE Death Neoplasm	Metastases to liver	Insulin icodec
NN1436-4477/455002	852745	SAE Death Neoplasm AE leading to permanent discontinuation of trial product	Pancreatic neoplasm	Insulin icodec
NN1436-4477/456002	792198	SAE Death Neoplasm AE leading to permanent discontinuation of trial product	Glioblastoma multiforme	Insulin icodec
NN1436-4477/456006	820673	SAE Death SUSAR AE leading to permanent discontinuation of trial product	Death	Insulin glargine
NN1436-4477/604011	851236	SAE Death AE leading to permanent discontinuation of trial product	Acute coronary syndrome	Insulin icodec
ONWARDS 2				
NN1436-4478/504008	858712	SAE Death	Acute respiratory failure	Insulin icodec
NN1436-4478/504008	858712	SAE Death	COVID-19	Insulin icodec
NN1436-4478/505005	850991	SAE Death	COVID-19	Insulin icodec
NN1436-4478/601005	836738	SAE Death	Thrombotic stroke	Insulin degludec
NN1436-4478/804006	830847	SAE Death	Pancreatic carcinoma metastatic	Insulin degludec
ONWARDS 3				
NN1436-4479/314008	853123	SAE, Death, Rare event, Adverse event leading to permanent discontinuation of trial product	Cardio-respiratory arrest	Insulin icodec
NN1436-4479/716004	872864	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Acute myocardial infarction	Insulin degludec
NN1436-4479/901010	912860	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Sepsis	Insulin icodec
ONWARDS 4				
NN1436-4480/304004	885449	SAE, Death	Gastrointestinal haemorrhage	Insulin glargine
NN1436-4480/311015	902235	SAE, Death, Rare event	Acute kidney injury	Insulin icodec
NN1436-4480/311015	902235	SAE, Death	Chronic kidney disease	Insulin icodec
NN1436-4480/311015	902235	SAE, Death, Rare event	Multiple organ dysfunction syndrome	Insulin icodec
NN1436-4480/905004	890611	SAE, Death	COVID-19 pneumonia	Insulin icodec
ONWARDS 5				
NN1436-4481/104008	932965	SAE, Death, Neoplasm	Breast cancer metastatic	OD analogues

Unique subject ID	Case Number	Reason(s) for Narrative	Preferred Term	Actual treatment
NN1436-4481/111006	902402	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Death	OD analogues
NN1436-4481/205028	878647	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Cardiac failure	Insulin icodec
NN1436-4481/501007	896563	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Arteriosclerosis	Insulin icodec
NN1436-4481/550005	887273	SAE, Death, Rare event, Adverse event leading to permanent discontinuation of trial product	Cardiac arrest	OD analogues
NN1436-4481/551003	884597	SAE, Death, Neoplasm, Adverse event leading to permanent discontinuation of trial product	Adenocarcinoma pancreas	Insulin icodec
NN1436-4481/564006	845256	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Myocardial infarction	OD analogues
NN1436-4481/578002	887275	SAE, Death	COVID-19 pneumonia	OD analogues
NN1436-4481/601002	901721	SAE, Death, Adverse event leading to permanent discontinuation of trial product	COVID-19 pneumonia	OD analogues
NN1436-4481/601002	901721	SAE, Death	Respiratory failure	OD analogues
NN1436-4481/805002	905426	SAE, Death, Adverse event leading to permanent discontinuation of trial product	Death	OD analogues
ONWARDS 6				
NN1436-4625/618007	893376	SAE, Death, AE leading to permanent discontinuation of trial product	Haemorrhage intracranial	Insulin icodec

3 Narratives for phase 3a pool

3.1 Hypoglycaemia – serious adverse events

This overview includes all SAEs of hypoglycaemia reported for the phase 3a ONWARDS programme.

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 3				
NN1436-4479/504010	896137	SAE	Hypoglycaemia	Insulin degludec
ONWARDS 4				
NN1436-4480/104005	838252	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4480/201009	894717	SAE	Hypoglycaemia	Insulin icodec
NN1436-4480/311006	838561	SAE	Hypoglycaemic coma	Insulin glargine
NN1436-4480/311015	902243	SAE, SUSAR	Hypoglycaemia	Insulin icodec
ONWARDS 5				
NN1436-4481/202001	846506	SAE	Hypoglycaemia	OD analogue
NN1436-4481/529001	841757	SAE	Hypoglycaemia	OD analogue
NN1436-4481/814005	952833	SAE	Hypoglycaemic unconsciousness	Insulin icodec
ONWARDS 6				
NN1436-4625/201001	845823	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/201001	862489	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/201001	862493	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/252010	891068	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/408005	900640	SAE, SUSAR	Hypoglycaemic seizure	Insulin icodec
NN1436-4625/601013	881433	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/804003	870956	SAE	Hypoglycaemic seizure	Insulin degludec
NN1436-4625/805007	907181	SAE, SUSAR	Hypoglycaemia	Insulin icodec

3.2 Neoplasms

3.2.1 Neoplasms - serious adverse events – in-trial

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1				
NN1436-4477/117003	804641	SAE Neoplasm	Hepatocellular carcinoma	Insulin glargine
NN1436-4477/117003	804641	SAE Neoplasm	Renal cell carcinoma	Insulin glargine
NN1436-4477/301002	857077	SAE Neoplasm	Basal cell carcinoma	Insulin icodec
NN1436-4477/404005	846001	SAE Neoplasm	Colon cancer	Insulin glargine
NN1436-4477/404005	844520	SAE Neoplasm AE leading to permanent discontinuation of trial product	Ovarian cancer metastatic	Insulin glargine
NN1436-4477/407011	890237	SAE Neoplasm	Large intestine polyp	Insulin glargine
NN1436-4477/455002	852745	SAE Death Neoplasm	Metastases to liver	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4477/455002	852745	SAE Death Neoplasm AE leading to permanent discontinuation of trial product	Pancreatic neoplasm	Insulin icodec
NN1436-4477/456002	792198	SAE Death Neoplasm AE leading to permanent discontinuation of trial product	Glioblastoma multiforme	Insulin icodec
NN1436-4477/715004	898701	SAE Neoplasm	Malignant melanoma in situ	Insulin glargine
ONWARDS 3				
NN1436-4479/107008	875372	SAE, Neoplasm	Renal cyst	Insulin icodec
NN1436-4479/110007	869272	SAE, Neoplasm	Adenocarcinoma of colon	Insulin degludec
NN1436-4479/309004	888439	SAE, Neoplasm	Colorectal cancer	Insulin icodec
NN1436-4479/504001	843733	SAE, Neoplasm	Lung adenocarcinoma	Insulin degludec
NN1436-4479/901010	912860	SAE, Neoplasm	Lung cancer metastatic	Insulin icodec
NN1436-4479/953021	904268	SAE, Neoplasm, Adverse event leading to permanent discontinuation of trial product	Adenocarcinoma pancreas	Insulin icodec
ONWARDS 4				
NN1436-4480/311004	879380	SAE, Neoplasm	Uterine cancer	Insulin glargine
NN1436-4480/311004	899606	SAE, Neoplasm	Small intestine neuroendocrine tumour	Insulin glargine
NN1436-4480/430005	896108	SAE, Neoplasm	Lung adenocarcinoma	Insulin glargine
NN1436-4480/905001	857329	SAE, Neoplasm	Small cell lung cancer	Insulin icodec
NN1436-4480/906013	868609	SAE, Neoplasm	Pancreatic neoplasm	Insulin icodec
ONWARDS 5				
NN1436-4481/101006	867708	SAE, Neoplasm	Lung cancer metastatic	OD analogues
NN1436-4481/104008	932965	SAE, Death, Neoplasm	Breast cancer metastatic	OD analogues
NN1436-4481/106001	888845	SAE, Neoplasm	Malignant melanoma	OD analogues
NN1436-4481/205033	932036	SAE, Neoplasm	Uterine leiomyoma	OD analogues
NN1436-4481/213006	875854	SAE, Neoplasm	Skin neoplasm excision	OD analogues
NN1436-4481/529001	841757	SAE, Neoplasm	Benign renal neoplasm	OD analogues
NN1436-4481/529005	934210	SAE, Neoplasm	Bowen's disease	OD analogues
NN1436-4481/535001	838229	SAE, Neoplasm	Invasive ductal breast carcinoma	Insulin icodec
NN1436-4481/535001	838229	SAE, Neoplasm	Invasive lobular breast carcinoma	Insulin icodec
NN1436-4481/545002	902223	SAE, Neoplasm	Endometrial adenocarcinoma	OD analogues
NN1436-4481/549002	870979	SAE, Neoplasm	Bladder cancer	Insulin icodec
NN1436-4481/551003	884597	SAE, Death, Neoplasm, Adverse event leading to permanent discontinuation of trial product	Adenocarcinoma pancreas	Insulin icodec
NN1436-4481/601014	910165	SAE, Neoplasm	Large intestine polyp	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4481/602021	902222	SAE, Neoplasm	Basal cell carcinoma	OD analogues
NN1436-4481/607001	849244	SAE, Neoplasm	Invasive breast carcinoma	OD analogues
NN1436-4481/611003	826225	SAE, Neoplasm	Colorectal cancer	Insulin icodec
NN1436-4481/709003	810146	SAE, Neoplasm	Metastases to liver	Insulin icodec
NN1436-4481/709003	810146	SAE, Neoplasm	Pancreatic carcinoma	Insulin icodec
NN1436-4481/810001	816759	SAE, Neoplasm	Metastases to liver	OD analogues
NN1436-4481/810001	816759	SAE, Neoplasm	Pancreatic carcinoma	OD analogues

3.2.2 Neoplasms - non-serious adverse events – in-trial

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/102005	Neoplasm	Acrochordon	Insulin icodec
NN1436-4477/103004	Neoplasm	Uterine polyp	Insulin icodec
NN1436-4477/108004	Neoplasm	Basal cell carcinoma	Insulin glargine
NN1436-4477/108004	Neoplasm	Dysplastic naevus	Insulin glargine
NN1436-4477/108004	Neoplasm	Actinic keratosis	Insulin glargine
NN1436-4477/113004	Neoplasm	Basal cell carcinoma	Insulin glargine
NN1436-4477/114002	Neoplasm	Large intestinal polypectomy	Insulin glargine
NN1436-4477/122001	Neoplasm	Rectal polyp	Insulin glargine
NN1436-4477/128002	Neoplasm	Synovial cyst	Insulin icodec
NN1436-4477/145006	Neoplasm	Renal cyst	Insulin icodec
NN1436-4477/154001	Neoplasm	Ovarian cyst	Insulin icodec
NN1436-4477/206006	Neoplasm	Rectal polyp	Insulin icodec
NN1436-4477/214009	Neoplasm	Laryngeal cyst	Insulin icodec
NN1436-4477/401007	Neoplasm	Gastric polyps	Insulin icodec
NN1436-4477/401015	Neoplasm	Hepatic cyst	Insulin glargine
NN1436-4477/403016	Neoplasm	Dermal cyst	Insulin glargine
NN1436-4477/404001	Neoplasm	Neoplasm skin	Insulin icodec
NN1436-4477/404005	Neoplasm	Large intestine polyp	Insulin glargine
NN1436-4477/404005	Neoplasm	Uterine leiomyoma	Insulin glargine
NN1436-4477/404005	Neoplasm	Gastric polyps	Insulin glargine
NN1436-4477/405014	Neoplasm	Prostate cancer	Insulin icodec
NN1436-4477/407011	Neoplasm	Large intestine polyp	Insulin glargine
NN1436-4477/409014	Neoplasm	Synovial cyst	Insulin icodec
NN1436-4477/409014	Neoplasm	Haemangioma of liver	Insulin icodec
NN1436-4477/457001	Neoplasm	Renal cyst	Insulin icodec

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4477/457001	Neoplasm	Large intestine polyp	Insulin icodec
NN1436-4477/457013	Neoplasm	Salivary gland neoplasm	Insulin icodec
NN1436-4477/502004	Neoplasm	Crohn's disease	Insulin glargine
NN1436-4477/505003	Neoplasm	Dermal cyst	Insulin glargine
NN1436-4477/605006	Neoplasm	Seborrhoeic keratosis	Insulin icodec
NN1436-4477/605006	Neoplasm	Seborrhoeic keratosis	Insulin icodec
NN1436-4477/715001	Neoplasm	Seborrhoeic keratosis	Insulin icodec
NN1436-4477/851020	Neoplasm	Oral fibroma	Insulin icodec
NN1436-4477/901024	Neoplasm	Bone cyst	Insulin icodec
ONWARDS 2			
NN1436-4478/204001	Neoplasm	Dermal cyst	Insulin degludec
NN1436-4478/218004	Neoplasm	Renal cyst	Insulin icodec
NN1436-4478/227001	Neoplasm	Large intestine polyp	Insulin icodec
NN1436-4478/306007	Neoplasm	Colon adenoma	Insulin icodec
NN1436-4478/805004	Neoplasm	Cervical polyp	Insulin icodec
NN1436-4478/806001	Neoplasm	Lymphangioma	Insulin degludec
NN1436-4478/902004	Neoplasm	Gallbladder polyp	Insulin icodec
NN1436-4478/902012	Neoplasm	Large intestine polyp	Insulin degludec
NN1436-4478/903011	Neoplasm	Gastric polyps	Insulin degludec
NN1436-4478/906001	Neoplasm	Breast cancer	Insulin degludec
ONWARDS 3			
NN1436-4479/102004	Neoplasm	Skin papilloma	Insulin icodec
NN1436-4479/106011	Neoplasm	Colon adenoma	Insulin icodec
NN1436-4479/107006	Neoplasm	Vocal cord polyp	Insulin degludec
NN1436-4479/107007	Neoplasm	Gastric polyps	Insulin icodec
NN1436-4479/112002	Neoplasm	Renal cyst	Insulin icodec
NN1436-4479/113006	Neoplasm	Leukoplakia	Insulin degludec
NN1436-4479/504001	Neoplasm	Adrenal adenoma	Insulin degludec
NN1436-4479/901010	Neoplasm	Bladder papilloma	Insulin icodec
ONWARDS 4			
NN1436-4480/101012	Neoplasm	Renal cyst	Insulin icodec
NN1436-4480/103014	Neoplasm	Gallbladder polyp	Insulin glargine
NN1436-4480/107008	Neoplasm	Infected dermal cyst	Insulin icodec
NN1436-4480/303009	Neoplasm	Adrenal adenoma	Insulin glargine
NN1436-4480/303012	Neoplasm	Paranasal cyst	Insulin glargine
NN1436-4480/311004	Neoplasm	Uterine leiomyoma	Insulin glargine
NN1436-4480/311010	Neoplasm	Renal cyst	Insulin glargine
NN1436-4480/406001	Neoplasm	Paranasal cyst	Insulin glargine

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4480/414001	Neoplasm	Cyst	Insulin glargine
NN1436-4480/420001	Neoplasm	Bone cyst	Insulin glargine
NN1436-4480/802006	Neoplasm	Osteoma	Insulin icodec
NN1436-4480/804008	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
ONWARDS 5			
NN1436-4481/102005	Neoplasm	Large intestine polyp	OD analogues
NN1436-4481/104008	Neoplasm	Renal hamartoma	OD analogues
NN1436-4481/104008	Neoplasm	Metastases to bone marrow	OD analogues
NN1436-4481/104008	Neoplasm	Metastases to lymph nodes	OD analogues
NN1436-4481/104008	Neoplasm	Malignant peritoneal neoplasm	OD analogues
NN1436-4481/105001	Neoplasm	Colon adenoma	Insulin icodec
NN1436-4481/205025	Neoplasm	Carbohydrate antigen 19-9 increased	OD analogues
NN1436-4481/507002	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4481/507002	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4481/507007	Neoplasm	Synovial cyst	OD analogues
NN1436-4481/545002	Neoplasm	Squamous cell carcinoma of skin	OD analogues
NN1436-4481/551003	Neoplasm	Lipoma	Insulin icodec
NN1436-4481/571001	Neoplasm	Gastrointestinal tract adenoma	OD analogues
NN1436-4481/571001	Neoplasm	Large intestine polyp	OD analogues
NN1436-4481/575002	Neoplasm	Squamous cell carcinoma of skin	Insulin icodec
NN1436-4481/602025	Neoplasm	Rectal polyp	OD analogues
NN1436-4481/607003	Neoplasm	Prostatic adenoma	OD analogues
NN1436-4481/609001	Neoplasm	Renal cyst	OD analogues
NN1436-4481/611003	Neoplasm	Renal neoplasm	Insulin icodec
NN1436-4481/703008	Neoplasm	Renal cyst	OD analogues
NN1436-4481/705010	Neoplasm	Renal cyst	Insulin icodec
NN1436-4481/705010	Neoplasm	Rectal polyp	Insulin icodec
NN1436-4481/709003	Neoplasm	Large intestine polyp	Insulin icodec
NN1436-4481/801007	Neoplasm	Myxoma	OD analogues
NN1436-4481/806003	Neoplasm	Renal cyst	OD analogues
NN1436-4481/807005	Neoplasm	Large intestine polyp	OD analogues
NN1436-4481/811002	Neoplasm	Prostatic specific antigen increased	Insulin icodec

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4481/816001	Neoplasm	Uterine polyp	Insulin icodec
NN1436-4481/837002	Neoplasm	Prostatic specific antigen increased	Insulin icodec
NN1436-4481/838002	Neoplasm	Testicular cyst	OD analogues
NN1436-4481/843001	Neoplasm	Cyst	OD analogues
ONWARDS 6			
NN1436-4625/505002	Neoplasm	Dermal cyst	Insulin icodec
NN1436-4625/619001	Neoplasm	Uterine leiomyoma	Insulin degludec
NN1436-4625/621003	Neoplasm	Infected cyst	Insulin degludec
NN1436-4625/625001	Neoplasm	Eye naevus	Insulin icodec
NN1436-4625/627004	Neoplasm	Melanocytic naevus	Insulin icodec
NN1436-4625/756005	Neoplasm	Skin neoplasm excision	Insulin icodec
NN1436-4625/803002	Neoplasm	Gallbladder polyp	Insulin icodec
NN1436-4625/805004	Neoplasm	Fibrocystic breast disease	Insulin degludec
NN1436-4625/903002	Neoplasm	Haemangioma of liver	Insulin icodec
NN1436-4625/903011	Neoplasm	Benign neoplasm of thyroid gland	Insulin icodec
NN1436-4625/903012	Neoplasm	Gallbladder polyp	Insulin degludec
NN1436-4625/904001	Neoplasm	Renal cyst	Insulin degludec
NN1436-4625/904003	Neoplasm	Gastric polyps	Insulin degludec
NN1436-4625/904003	Neoplasm	Benign renal neoplasm	Insulin degludec
NN1436-4625/904003	Neoplasm	Uterine leiomyoma	Insulin degludec
NN1436-4625/904007	Neoplasm	Dermal cyst	Insulin degludec
NN1436-4625/904012	Neoplasm	Synovial cyst	Insulin icodec
NN1436-4625/907004	Neoplasm	Gastric polyps	Insulin degludec
NN1436-4625/907007	Neoplasm	Gallbladder polyp	Insulin degludec

3.3 Diabetic retinopathy or maculopathy

3.3.1 Diabetic retinopathy or maculopathy - serious adverse events – in-trial

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1				
NN1436-4477/213005	886230	SAE SUSAR Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin glargine
ONWARDS 3				
NN1436-4479/402006	903161	SAE, Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
ONWARDS 4				
NN1436-4480/302014	910222	SAE, Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin glargine
NN1436-4480/311012	899170	SAE, SUSAR, Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin glargine

NN1436-4480/311012	899170	SAE, SUSAR, Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin glargine

3.3.2 Diabetic retinopathy or maculopathy - non-serious adverse events – in-trial

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/214001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4477/214001	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4477/214001	Diabetic retinopathy or maculopathy	Post thrombotic retinopathy	Insulin icodec
NN1436-4477/301004	Diabetic retinopathy or maculopathy	Retinal vein occlusion	Insulin glargine
NN1436-4477/301004	Diabetic retinopathy or maculopathy	Retinal detachment	Insulin glargine
NN1436-4477/301011	Diabetic retinopathy or maculopathy	Retinal tear	Insulin icodec
NN1436-4477/403005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4477/403006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4477/404007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4477/407007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4477/407012	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4477/408002	Diabetic retinopathy or maculopathy	Retinal artery occlusion	Insulin glargine
NN1436-4477/409003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4477/410001	Diabetic retinopathy or maculopathy	Scintillating scotoma	Insulin glargine
NN1436-4477/454007	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4477/605005	Diabetic retinopathy or maculopathy	Retinal aneurysm	Insulin icodec
NN1436-4477/605008	Diabetic retinopathy or maculopathy	Vitreous detachment	Insulin icodec
NN1436-4477/904008	Diabetic retinopathy or maculopathy	Vitreous haemorrhage	Insulin glargine
ONWARDS 2			
NN1436-4478/205002	Diabetic retinopathy or maculopathy	Epiretinal membrane	Insulin icodec
NN1436-4478/206001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/209005	Diabetic retinopathy or maculopathy	Retinal exudates	Insulin icodec
NN1436-4478/210006	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4478/210010	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/220004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/220008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/222001	Diabetic retinopathy or maculopathy	Dry age-related macular degeneration	Insulin icodec
NN1436-4478/303002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/303002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec

NN1436-4478/303003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/303003	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4478/303006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/303007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/303007	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4478/303008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/303009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/303009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/303009	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin degludec
NN1436-4478/303012	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/303012	Diabetic retinopathy or maculopathy	Visual acuity reduced	Insulin degludec
NN1436-4478/303016	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/306011	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/402001	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin degludec
NN1436-4478/403005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/403007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/403008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/403008	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4478/601014	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/701002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/701005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/704001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/803013	Diabetic retinopathy or maculopathy	Vitreous haemorrhage	Insulin icodec
NN1436-4478/805006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/805010	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin degludec
NN1436-4478/805020	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/808008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/808012	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4478/809001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4478/902003	Diabetic retinopathy or maculopathy	Retinal haemorrhage	Insulin icodec

NN1436-4478/903005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
ONWARDS 3			
NN1436-4479/101006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/101010	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/104002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/106027	Diabetic retinopathy or maculopathy	Retinopathy	Insulin degludec
NN1436-4479/109001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/110001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/110005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/111003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/113005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/113006	Diabetic retinopathy or maculopathy	Retinal degeneration	Insulin degludec
NN1436-4479/113006	Diabetic retinopathy or maculopathy	Chorioretinal atrophy	Insulin degludec
NN1436-4479/202010	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/304002	Diabetic retinopathy or maculopathy	Macular hole	Insulin degludec
NN1436-4479/304002	Diabetic retinopathy or maculopathy	Epiretinal membrane	Insulin degludec
NN1436-4479/323002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/330002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/402023	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/703006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/703009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/703009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4479/710003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/716005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/803001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/803001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/851003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/851007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/904001	Diabetic retinopathy or maculopathy	Retinal aneurysm	Insulin degludec
NN1436-4479/904003	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin icodec
NN1436-4479/904003	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin icodec
NN1436-4479/904007	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec

NN1436-4479/951002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/951016	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/953023	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin degludec
NN1436-4479/954001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4479/954013	Diabetic retinopathy or maculopathy	Vitreous floaters	Insulin degludec
NN1436-4479/954015	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
ONWARDS 4			
NN1436-4480/101007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/101009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/101011	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/101013	Diabetic retinopathy or maculopathy	Retinal exudates	Insulin glargine
NN1436-4480/102003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/102006	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin glargine
NN1436-4480/102012	Diabetic retinopathy or maculopathy	Vitreous haemorrhage	Insulin icodec
NN1436-4480/102012	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105008	Diabetic retinopathy or maculopathy	Visual impairment	Insulin glargine
NN1436-4480/105009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/106004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/106004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/106008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/109001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/109001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/201005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/202015	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/202030	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/301013	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec

NN1436-4480/302014	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/303003	Diabetic retinopathy or maculopathy	Age-related macular degeneration	Insulin icodec
NN1436-4480/309001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/309007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/404006	Diabetic retinopathy or maculopathy	Retinal haemorrhage	Insulin icodec
NN1436-4480/406004	Diabetic retinopathy or maculopathy	Retinal drusen	Insulin glargine
NN1436-4480/406005	Diabetic retinopathy or maculopathy	Vitreous detachment	Insulin icodec
NN1436-4480/420001	Diabetic retinopathy or maculopathy	Macular degeneration	Insulin glargine
NN1436-4480/420001	Diabetic retinopathy or maculopathy	Vitreous haemorrhage	Insulin glargine
NN1436-4480/420001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/420004	Diabetic retinopathy or maculopathy	Retinal drusen	Insulin icodec
NN1436-4480/429004	Diabetic retinopathy or maculopathy	Retinal exudates	Insulin glargine
NN1436-4480/429004	Diabetic retinopathy or maculopathy	Retinal detachment	Insulin glargine
NN1436-4480/430003	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4480/430004	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4480/431005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/431005	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4480/431012	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/431012	Diabetic retinopathy or maculopathy	Retinal scar	Insulin icodec
NN1436-4480/431014	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/603004	Diabetic retinopathy or maculopathy	Macular oedema	Insulin glargine
NN1436-4480/603005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/703002	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4480/703003	Diabetic retinopathy or maculopathy	Retinal deposits	Insulin icodec
NN1436-4480/801001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/801001	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4480/801003	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin glargine
NN1436-4480/801005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/801006	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin glargine
NN1436-4480/801006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/801008	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin glargine
NN1436-4480/801009	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/801010	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin glargine

NN1436-4480/802003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/802010	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4480/803001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin glargine
NN1436-4480/803003	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4480/804008	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4480/804008	Diabetic retinopathy or maculopathy	Retinal haemorrhage	Insulin icodec
NN1436-4480/806007	Diabetic retinopathy or maculopathy	Retinal vascular disorder	Insulin glargine
ONWARDS 5			
NN1436-4481/108005	Diabetic retinopathy or maculopathy	Retinal artery occlusion	OD analogues
NN1436-4481/203002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/205002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/205002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/205020	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/205020	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/205020	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4481/205020	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4481/206005	Diabetic retinopathy or maculopathy	Macular degeneration	OD analogues
NN1436-4481/207001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/207001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/207003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/214001	Diabetic retinopathy or maculopathy	Macular oedema	OD analogues
NN1436-4481/214002	Diabetic retinopathy or maculopathy	Maculopathy	Insulin icodec
NN1436-4481/506001	Diabetic retinopathy or maculopathy	Retinal haemorrhage	Insulin icodec
NN1436-4481/506003	Diabetic retinopathy or maculopathy	Retinal degeneration	Insulin icodec
NN1436-4481/507002	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4481/507002	Neoplasm, Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4481/507002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/507007	Diabetic retinopathy or maculopathy	Epiretinal membrane	OD analogues
NN1436-4481/517004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/520005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/520008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec

NN1436-4481/528002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/535002	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4481/537003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/542001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/547002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/547002	Diabetic retinopathy or maculopathy	Cystoid macular oedema	OD analogues
NN1436-4481/547009	Diabetic retinopathy or maculopathy	Retinal tear	OD analogues
NN1436-4481/547009	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	OD analogues
NN1436-4481/551001	Diabetic retinopathy or maculopathy	Vitreous detachment	Insulin icodec
NN1436-4481/552002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/553006	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	OD analogues
NN1436-4481/553007	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4481/553012	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4481/553014	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/568001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/574004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/577001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/601004	Diabetic retinopathy or maculopathy	Maculopathy	OD analogues
NN1436-4481/601005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/601005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/608002	Diabetic retinopathy or maculopathy	Arteriosclerotic retinopathy	Insulin icodec
NN1436-4481/608002	Diabetic retinopathy or maculopathy	Amaurosis fugax	Insulin icodec
NN1436-4481/608003	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	OD analogues
NN1436-4481/612002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/613002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/704009	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	OD analogues
NN1436-4481/705012	Diabetic retinopathy or maculopathy	Macular oedema	OD analogues
NN1436-4481/706002	Diabetic retinopathy or maculopathy	Age-related macular degeneration	Insulin icodec
NN1436-4481/706008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/801001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/801001	Diabetic retinopathy or maculopathy	Visual impairment	Insulin icodec
NN1436-4481/801007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues

NN1436-4481/801017	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/808010	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4481/812009	Diabetic retinopathy or maculopathy	Macular oedema	OD analogues
NN1436-4481/812014	Diabetic retinopathy or maculopathy	Visual impairment	Insulin icodec
NN1436-4481/820001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/829001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/841001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4481/841004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	OD analogues
NN1436-4481/843001	Diabetic retinopathy or maculopathy	Macular degeneration	OD analogues
ONWARDS 6			
NN1436-4625/101003	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin degludec
NN1436-4625/101004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/101005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/202002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/203001	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4625/203001	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4625/205002	Diabetic retinopathy or maculopathy	Arteriosclerotic retinopathy	Insulin icodec
NN1436-4625/205002	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4625/304003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/305003	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin degludec
NN1436-4625/305004	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4625/308002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/352003	Diabetic retinopathy or maculopathy	Photopsia	Insulin degludec
NN1436-4625/352003	Diabetic retinopathy or maculopathy	Vitreous floaters	Insulin degludec
NN1436-4625/401001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/402001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/405007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/500003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/508004	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin degludec
NN1436-4625/508008	Diabetic retinopathy or maculopathy	Retinopathy hypertensive	Insulin icodec
NN1436-4625/508008	Diabetic retinopathy or maculopathy	Retinal vascular disorder	Insulin icodec
NN1436-4625/609005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/610003	Diabetic retinopathy or maculopathy	Vitreous floaters	Insulin degludec
NN1436-4625/612001	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec

NN1436-4625/618002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/618005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/618005	Diabetic retinopathy or maculopathy	Diabetic retinal oedema	Insulin icodec
NN1436-4625/619005	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin icodec
NN1436-4625/623005	Diabetic retinopathy or maculopathy	Epiretinal membrane	Insulin icodec
NN1436-4625/625001	Diabetic retinopathy or maculopathy	Eye naevus	Insulin icodec
NN1436-4625/625002	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/625002	Diabetic retinopathy or maculopathy	Epiretinal membrane	Insulin degludec
NN1436-4625/625005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/628004	Diabetic retinopathy or maculopathy	Macular oedema	Insulin degludec
NN1436-4625/628004	Diabetic retinopathy or maculopathy	Retinopathy	Insulin degludec
NN1436-4625/629001	Diabetic retinopathy or maculopathy	Macular oedema	Insulin icodec
NN1436-4625/629002	Diabetic retinopathy or maculopathy	Non-proliferative retinopathy	Insulin icodec
NN1436-4625/629003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/701003	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/753006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/753008	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/901004	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/901013	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/902007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/903006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/903009	Diabetic retinopathy or maculopathy	Vitreous detachment	Insulin degludec
NN1436-4625/906005	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/906006	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin icodec
NN1436-4625/907001	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/907007	Diabetic retinopathy or maculopathy	Diabetic retinopathy	Insulin degludec
NN1436-4625/907007	Diabetic retinopathy or maculopathy	Vitreous detachment	Insulin degludec

3.4 Hyperglycaemia incl. diabetic ketoacidosis

3.4.1 Hyperglycaemia incl. diabetic ketoacidosis - serious adverse events – in-trial

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment

ONWARDS 4				
NN1436-4480/309001	845723	SAE, Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
ONWARDS 6				
NN1436-4625/755005	864010	SAE, Hyperglycaemia incl. diabetic ketoacidosis	Blood glucose increased	Insulin degludec

3.4.2 Hyperglycaemia incl. diabetic ketoacidosis - non-serious adverse events – on-treatment

Unique subject ID	Reason(S) for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/155002	Hyperglycaemia incl. diabetic ketoacidosis	Diabetes mellitus	Insulin glargine
NN1436-4477/160002	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4477/205006	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4477/456006	Hyperglycaemia incl. diabetic ketoacidosis	Blood glucose increased	Insulin glargine
NN1436-4477/901019	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4477/952011	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4477/954001	Hyperglycaemia incl. diabetic ketoacidosis	Glycosylated haemoglobin increased	Insulin icodec
NN1436-4477/956006	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4477/956007	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
ONWARDS 2			
NN1436-4478/216005	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin degludec
NN1436-4478/504008	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
NN1436-4478/702003	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
ONWARDS 3			
NN1436-4479/201003	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
NN1436-4479/201012	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin degludec
NN1436-4479/714001	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
NN1436-4479/714001	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
ONWARDS 4			
NN1436-4480/311006	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4480/311012	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4480/426002	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
NN1436-4480/505011	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin glargine
ONWARDS 5			
NN1436-4481/111005	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec

Unique subject ID	Reason(S) for narrative	Preferred term	Actual treatment
NN1436-4481/506007	Hyperglycaemia incl. diabetic ketoacidosis	Diabetes mellitus	Insulin icodec
NN1436-4481/553005	Hyperglycaemia incl. diabetic ketoacidosis	Hyperglycaemia	Insulin icodec
NN1436-4481/559004	Hyperglycaemia incl. diabetic ketoacidosis	Insulin resistance	OD analogues
NN1436-4481/707006	Hyperglycaemia incl. diabetic ketoacidosis	Glycosylated haemoglobin increased	OD analogues
NN1436-4481/707006	Hyperglycaemia incl. diabetic ketoacidosis	Glycosylated haemoglobin increased	OD analogues
NN1436-4481/707011	Hyperglycaemia incl. diabetic ketoacidosis	Glycosylated haemoglobin increased	OD analogues
NN1436-4481/812018	Hyperglycaemia incl. diabetic ketoacidosis	Diabetes mellitus	Insulin icodec
NN1436-4481/813001	Hyperglycaemia incl. diabetic ketoacidosis	Diabetes mellitus inadequate control	Insulin icodec
ONWARDS 6			
NN1436-4625/205003	Hyperglycaemia incl. diabetic ketoacidosis	Insulin resistance	Insulin degludec

3.5 Hypokalaemia

3.5.1 Hypokalaemia - serious adverse events – in-trial

No reported events.

3.5.2 Hypokalaemia - non-serious adverse events – on-treatment

Unique subject ID	Reason(s) for narrative	Preferred term	Treatment group
ONWARDS 1			
NN1436-4477/107002	Hypokalaemia	Hypokalaemia	Insulin icodec
NN1436-4477/138003	Hypokalaemia	Hypokalaemia	Insulin glargine
ONWARDS 4			
NN1436-4480/906013	Hypokalaemia	Hypokalaemia	Insulin icodec

3.6 Other microvascular diabetic complications

3.6.1 Other microvascular diabetic complications - serious adverse events – in-trial

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 3				
NN1436-4479/106002	866807	SAE, Other microvascular diabetic complications	Diabetic neuropathy	Insulin degludec
ONWARDS 4				
NN1436-4480/414002	861194	SAE, Other microvascular diabetic complications	Diabetic foot infection	Insulin icodec

3.6.2 Other microvascular diabetic complications - non-serious adverse events – in-trial

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/144001	Other microvascular diabetic complications	Diabetic neuropathy	Insulin glargine

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4477/153002	Other microvascular diabetic complications	Diabetic neuropathy	Insulin glargine
NN1436-4477/206006	Other microvascular diabetic complications	Diabetic nephropathy	Insulin icodec
NN1436-4477/301003	Other microvascular diabetic complications	Microalbuminuria	Insulin icodec
NN1436-4477/303003	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
NN1436-4477/304006	Other microvascular diabetic complications	Diabetic nephropathy	Insulin icodec
NN1436-4477/454002	Other microvascular diabetic complications	Diabetic foot	Insulin glargine
NN1436-4477/904013	Other microvascular diabetic complications	Diabetic neuropathy	Insulin glargine
ONWARDS 2			
NN1436-4478/102002	Other microvascular diabetic complications	Diabetic nephropathy	Insulin icodec
NN1436-4478/805010	Other microvascular diabetic complications	Diabetic neuropathy	Insulin degludec
ONWARDS 3			
NN1436-4479/202009	Other microvascular diabetic complications	Diabetic neuropathy	Insulin degludec
NN1436-4479/402015	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
NN1436-4479/713005	Other microvascular diabetic complications	Diabetic neuropathy	Insulin degludec
NN1436-4479/852007	Other microvascular diabetic complications	Neuropathic arthropathy	Insulin degludec
NN1436-4479/953003	Other microvascular diabetic complications	Diabetic nephropathy	Insulin degludec
NN1436-4479/953009	Other microvascular diabetic complications	Diabetic nephropathy	Insulin degludec
ONWARDS 4			
NN1436-4480/201028	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
NN1436-4480/309010	Other microvascular diabetic complications	Diabetic neuropathy	Insulin glargine
NN1436-4480/311006	Other microvascular diabetic complications	Diabetic neuropathy	Insulin glargine
NN1436-4480/805002	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
ONWARDS 5			
NN1436-4481/105002	Other microvascular diabetic complications	Microalbuminuria	OD analogues
NN1436-4481/105007	Other microvascular diabetic complications	Diabetic foot	OD analogues
NN1436-4481/114006	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
NN1436-4481/506006	Other microvascular diabetic complications	Diabetic neuropathy	OD analogues
NN1436-4481/545005	Other microvascular diabetic complications	Diabetic foot	Insulin icodec
NN1436-4481/611007	Other microvascular diabetic complications	Diabetic neuropathy	OD analogues
NN1436-4481/801014	Other microvascular diabetic complications	Diabetic neuropathy	OD analogues
NN1436-4481/831007	Other microvascular diabetic complications	Diabetic foot infection	OD analogues

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 6			
NN1436-4625/502003	Other microvascular diabetic complications	Microalbuminuria	Insulin icodec
NN1436-4625/806003	Other microvascular diabetic complications	Diabetic nephropathy	Insulin degludec
NN1436-4625/903010	Other microvascular diabetic complications	Diabetic neuropathy	Insulin icodec
NN1436-4625/907004	Other microvascular diabetic complications	Diabetic nephropathy	Insulin degludec

3.7 Clinically meaningful peripheral oedema

3.7.1 Clinically meaningful peripheral oedema - serious adverse events – in-trial

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 5				
NN1436-4481/703008	846512	SAE, Clinically meaningful peripheral oedema	Peripheral swelling	OD analogues

3.7.2 Clinically meaningful peripheral oedema - non-serious adverse events – on-treatment

Unique subject ID	Reason for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/138004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4477/138004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4477/143011	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4477/145001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4477/154001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4477/154004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4477/156005	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4477/404001	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4477/457005	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin glargine
NN1436-4477/501013	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4477/603004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4477/605008	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4477/711003	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4477/904006	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
ONWARDS 2			
NN1436-4478/206001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4478/306007	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
ONWARDS 3			
NN1436-4479/105007	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4479/105007	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4479/105012	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4479/330001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4479/904007	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4479/951011	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
ONWARDS 4			

Unique subject ID	Reason for narrative	Preferred term	Actual treatment
NN1436-4480/106004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4480/407005	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4480/429006	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
NN1436-4480/512002	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin glargine
NN1436-4480/512006	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin glargine
NN1436-4480/804006	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin glargine
ONWARDS 5			
NN1436-4481/521003	Clinically meaningful peripheral oedema	Oedema peripheral	OD analogues
NN1436-4481/521007	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4481/535001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4481/553010	Clinically meaningful peripheral oedema	Oedema peripheral	OD analogues
NN1436-4481/596001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4481/812001	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4481/814002	Clinically meaningful peripheral oedema	Peripheral swelling	Insulin icodec
NN1436-4481/814005	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
ONWARDS 6			
NN1436-4625/701003	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin degludec
NN1436-4625/751004	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec
NN1436-4625/903010	Clinically meaningful peripheral oedema	Oedema peripheral	Insulin icodec

3.8 Lipodystrophy

3.8.1 Lipodystrophy - serious adverse events – in-trial

No reported events.

3.8.2 Lipodystrophy - non-serious adverse events – in-trial

Unique subject ID	Reason for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/403004	Lipodystrophy	Lipohypertrophy	Insulin glargine
NN1436-4477/605003	Lipodystrophy	Lipodystrophy acquired	Insulin icodec
ONWARDS 4			
NN1436-4480/101009	Lipodystrophy	Lipohypertrophy	Insulin glargine

3.9 Localised amyloidosis

3.9.1 Localised amyloidosis - serious adverse events – in-trial

No reported events.

3.9.2 Localised amyloidosis - non-serious adverse events – in-trial

No reported events.

3.10 Injection site reaction – serious adverse events

No reported events.

3.11 Hypersensitivity - serious adverse events

The listed events cover both the events found by the MedDRA search and the systemic hypersensitivity events reported by the investigators.

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 2				
NN1436-4478/207003	863623	SAE, Hypersensitivity, Systemic hypersensitivity	Anaphylactic reaction	Insulin icodec
NN1436-4478/401002	804113	SAE, SUSAR, Hypersensitivity, Systemic hypersensitivity, Adverse event leading to permanent discontinuation of trial product	Anaphylactic reaction	Insulin degludec
ONWARDS 5				
NN1436-4481/206003	826227	SAE, Systemic hypersensitivity, Hypersensitivity, Adverse event leading to permanent discontinuation of trial product	Urticaria	Insulin icodec
NN1436-4481/206003	826227	SAE, SUSAR, Systemic hypersensitivity, Hypersensitivity, Adverse event leading to permanent discontinuation of trial product	Urticaria	Insulin icodec

3.12 Immunogenicity - serious adverse events

No reported events.

3.13 Rare event – serious adverse events

Unique subject ID	Case number	Reason(s) for Narrative	Preferred Term	Actual treatment
ONWARDS 1				
NN1436-4477/120003	783125	SAE, Rare event	Interstitial lung disease	Insulin icodec
NN1436-4477/120005	881729	SAE, Rare event	Atrioventricular block complete	Insulin glargine
NN1436-4477/204002	850488	SAE, Rare event	Atrial fibrillation	Insulin glargine
NN1436-4477/304006	913210	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4477/411008	911933	SAE, Rare event	Hydrocele	Insulin icodec
NN1436-4477/453005	828469	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4477/605006	863967	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4477/605006	897811	SAE, Rare event	Sinus tachycardia	Insulin icodec
NN1436-4477/605010	894703	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4477/851001	846898	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4477/851001	846898	SAE, Rare event	Atrial flutter	Insulin icodec
NN1436-4477/851016	805617	SAE, Rare event	Pancreatitis acute	Insulin glargine
NN1436-4477/904018	841379	SAE, Rare event	Hepatic cirrhosis	Insulin glargine
ONWARDS 2				
NN1436-4478/204006	832644	SAE, Rare event	Supraventricular tachycardia	Insulin icodec
NN1436-4478/401003	850474	SAE, Rare event	Syncope	Insulin icodec
ONWARDS 3				

Unique subject ID	Case number	Reason(s) for Narrative	Preferred Term	Actual treatment
NN1436-4479/314008	853123	SAE, Death, Rare event, Adverse event leading to permanent discontinuation of trial product	Cardio-respiratory arrest	Insulin icodec
NN1436-4479/315013	891979	SAE, Rare event	Acute kidney injury	Insulin icodec
NN1436-4479/901010	878290	SAE, Rare event	Renal failure	Insulin icodec
ONWARDS 4				
NN1436-4480/311015	902235	SAE, Death, Rare event	Acute kidney injury	Insulin icodec
NN1436-4480/311015	902235	SAE, Death, Rare event	Multiple organ dysfunction syndrome	Insulin icodec
ONWARDS 5				
NN1436-4481/104008	935362	SAE, Rare event	Loss of consciousness	OD analogue
NN1436-4481/105003	863621	SAE, Rare event	Atrial fibrillation	Insulin icodec
NN1436-4481/520005	869144	SAE, Rare event	Arrhythmia	Insulin icodec
NN1436-4481/521010	817147	SAE, Rare event	Cardiac arrest	OD analogue
NN1436-4481/529001	841757	SAE, Rare event	Acute kidney injury	OD analogue
NN1436-4481/534001	898821	SAE, Rare event	Pancytopenia	OD analogue
NN1436-4481/547009	905433	SAE, Rare event	Acute kidney injury	OD analogue
NN1436-4481/550005	887273	SAE, Death, Rare event, Adverse event leading to permanent discontinuation of trial product	Cardiac arrest	OD analogue
NN1436-4481/571005	840280	SAE, Rare event	Acute kidney injury	OD analogue
NN1436-4481/577002	902741	SAE, Rare event	Palpitations	OD analogue
NN1436-4481/577002	906772	SAE, Rare event	Ventricular tachycardia	OD analogue
NN1436-4481/601014	926117	SAE, Rare event	Clostridium difficile colitis	Insulin icodec
NN1436-4481/701003	831555	SAE, Rare event	Hypertrophic cardiomyopathy	OD analogue
NN1436-4481/704001	868156	SAE, Rare event	Atrial flutter	OD analogue
NN1436-4481/707013	848114	SAE, Rare event	Arrhythmia	Insulin icodec
NN1436-4481/812012	832336	SAE, Rare event	Supraventricular tachycardia	Insulin icodec

3.14 Suspected transmission of infectious agents – serious adverse events

No reported events

3.15 Medication error including misuse and abuse – serious adverse events

Unique subject ID	Case number	Reason(s) for Narrative	Preferred Term	Actual treatment
ONWARDS 3				
NN1436-4479/504010	896137	SAE, Medication error	Accidental overdose	Insulin degludec
ONWARDS 4				
NN1436-4480/311016	911934	SAE, Medication error	Overdose	Insulin glargine
ONWARDS 6				
NN1436-4625/203003	897776	SAE, SUSAR, Medication error	Product administration error	Insulin icodec

3.16 Serious adverse events not covered by safety focus areas

This overview includes all SAEs reported for the phase 3a ONWARDS programme that are not already listed as part of the safety focus areas or as fatal events in Section 2.

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1				
NN1436-4477/110004	856108	SAE	Coronary artery disease	Insulin icodec
NN1436-4477/111001	799978	SAE	Anaemia	Insulin icodec
NN1436-4477/111001	833894	SAE	Cardiac failure congestive	Insulin icodec
NN1436-4477/116002	868165	SAE	Post procedural stroke	Insulin glargine
NN1436-4477/120006	895268	SAE	Rib fracture	Insulin glargine
NN1436-4477/121003	809759	SAE	Cellulitis	Insulin glargine
NN1436-4477/122005	873567	SAE	Empyema	Insulin glargine
NN1436-4477/122005	873567	SAE	Sepsis	Insulin glargine
NN1436-4477/124005	813051	SAE	Acute kidney injury	Insulin glargine
NN1436-4477/124005	813051	SAE	Acute myocardial infarction	Insulin glargine
NN1436-4477/124005	813051	SAE	Acute pulmonary oedema	Insulin glargine
NN1436-4477/124005	813051	SAE	Acute respiratory failure	Insulin glargine
NN1436-4477/124005	813051	SAE	Atrial fibrillation	Insulin glargine
NN1436-4477/124005	813051	SAE	Blood loss anaemia	Insulin glargine
NN1436-4477/124005	813051	SAE	Clostridium difficile infection	Insulin glargine
NN1436-4477/124005	813051	SAE	Coronary artery disease	Insulin glargine
NN1436-4477/124005	813051	SAE	Left ventricular dysfunction	Insulin glargine
NN1436-4477/124005	813051	SAE	Pleural effusion	Insulin glargine
NN1436-4477/125002	881182	SAE	Angina unstable	Insulin icodec
NN1436-4477/125002	881182	SAE	Coronary artery disease	Insulin icodec
NN1436-4477/136002	881704	SAE	Peripheral arterial occlusive disease	Insulin icodec
NN1436-4477/139005	826231	SAE	Pneumonia	Insulin icodec
NN1436-4477/139005	870921	SAE	Hypertensive urgency	Insulin icodec
NN1436-4477/139005	872906	SAE	Bronchitis	Insulin icodec
NN1436-4477/142001	857334	SAE	Acute respiratory failure	Insulin icodec
NN1436-4477/142001	857334	SAE	Pneumonia	Insulin icodec
NN1436-4477/142001	857334	SAE	Respiratory syncytial virus infection	Insulin icodec
NN1436-4477/144007	857078	SAE	Coronary artery occlusion	Insulin icodec
NN1436-4477/150006	876840	SAE	Hyperkalaemia	Insulin icodec
NN1436-4477/157001	819811	SAE	Ureterolithiasis	Insulin glargine
NN1436-4477/204006	835029	SAE	Brachiocephalic arteriosclerosis	Insulin glargine
NN1436-4477/204006	835029	SAE	Thrombotic stroke	Insulin glargine
NN1436-4477/205005	856574	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4477/205006	853104	SAE	Laryngitis	Insulin glargine
NN1436-4477/206005	859574	SAE	COVID-19 pneumonia	Insulin glargine
NN1436-4477/206006	821935	SAE	COVID-19	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4477/206010	886048	SAE	Transient ischaemic attack	Insulin icodec
NN1436-4477/207005	836644	SAE	COVID-19	Insulin icodec
NN1436-4477/207010	853826	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4477/208009	854669	SAE	Coronavirus infection	Insulin glargine
NN1436-4477/208011	803199	SAE	Spinal pain	Insulin glargine
NN1436-4477/210005	849123	SAE	Myocardial infarction	Insulin glargine
NN1436-4477/211005	872509	SAE	Transient ischaemic attack	Insulin glargine
NN1436-4477/213007	859575	SAE	Presbyacusis	Insulin glargine
NN1436-4477/213007	862021	SAE	Otitis media acute	Insulin glargine
NN1436-4477/213008	865184	SAE	COVID-19 pneumonia	Insulin glargine
NN1436-4477/213010	893386	SAE	COVID-19	Insulin icodec
NN1436-4477/213010	896953	SAE	Angina unstable	Insulin icodec
NN1436-4477/213010	896953	SAE	Myocardial infarction	Insulin icodec
NN1436-4477/213010	900554	SAE	Coronary artery occlusion	Insulin icodec
NN1436-4477/214005	887628	SAE	Pneumonia	Insulin glargine
NN1436-4477/214008	802319	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4477/301002	818613	SAE	Plantar fasciitis	Insulin icodec
NN1436-4477/301004	879668	SAE	Endophthalmitis	Insulin glargine
NN1436-4477/301010	831175	SAE	Cerebral haemorrhage	Insulin icodec
NN1436-4477/301013	808632	SAE	Cardiac stress test abnormal	Insulin glargine
NN1436-4477/303005	881485	SAE	Anal abscess	Insulin glargine
NN1436-4477/304002	880916	SAE	Back pain	Insulin icodec
NN1436-4477/304002	917093	SAE	Uterine prolapse	Insulin icodec
NN1436-4477/304003	886733	SAE	Peripheral artery occlusion	Insulin icodec
NN1436-4477/305003	835500	SAE	Non-cardiac chest pain	Insulin glargine
NN1436-4477/402001	784309	SAE	COVID-19	Insulin glargine
NN1436-4477/404005	889202	SAE	Urinary tract infection	Insulin glargine
NN1436-4477/407006	851811	SAE	Meniscus injury	Insulin icodec
NN1436-4477/407007	835027	SAE	Radius fracture	Insulin glargine
NN1436-4477/408002	918329	SAE	Myocardial infarction	Insulin glargine
NN1436-4477/410003	807736	SAE	Benign prostatic hyperplasia	Insulin icodec
NN1436-4477/410007	884733	SAE	Removal of foreign body	Insulin glargine
NN1436-4477/411010	865555	SAE	Colitis ischaemic	Insulin icodec
NN1436-4477/451011	862503	SAE	Spinal pain	Insulin glargine
NN1436-4477/451011	893810	SAE	Lower limb fracture	Insulin glargine
NN1436-4477/451016	859581	SAE	Ureterolithiasis	Insulin icodec
NN1436-4477/453006	900095	SAE	Chronic coronary syndrome	Insulin icodec
NN1436-4477/453006	900095	SAE	Periprocedural myocardial infarction	Insulin icodec
NN1436-4477/453012	855633	SAE	Coronary artery disease	Insulin icodec
NN1436-4477/453012	898207	SAE	Cardiac failure	Insulin icodec
NN1436-4477/454006	828472	SAE	Peripheral artery stenosis	Insulin icodec
NN1436-4477/454006	844525	SAE	Peripheral artery stenosis	Insulin icodec
NN1436-4477/455006	845977	SAE	Endotracheal intubation complication	Insulin glargine

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4477/455006	845977	SAE	Inguinal hernia	Insulin glargine
NN1436-4477/455006	845977	SAE	Inguinal hernia	Insulin glargine
NN1436-4477/455006	845977	SAE	Umbilical hernia	Insulin glargine
NN1436-4477/456002	792198	SAE	Post procedural haemorrhage	Insulin icodec
NN1436-4477/457001	914531	SAE	Cervical radiculopathy	Insulin icodec
NN1436-4477/457011	880967	SAE	Diplopia	Insulin icodec
NN1436-4477/458003	896099	SAE	Myocardial infarction	Insulin icodec
NN1436-4477/501010	859143	SAE	Urinary tract obstruction	Insulin glargine
NN1436-4477/501012	902414	SAE	Acute myocardial infarction	Insulin glargine
NN1436-4477/502003	901082	SAE	Acute coronary syndrome	Insulin icodec
NN1436-4477/503004	917513	SAE	Deafness traumatic	Insulin glargine
NN1436-4477/505005	868168	SAE	Urinary tract infection	Insulin glargine
NN1436-4477/604010	856576	SAE	Myocardial infarction	Insulin icodec
NN1436-4477/605004	864476	SAE	Immunisation reaction	Insulin glargine
NN1436-4477/605004	864476	SAE	Immunisation reaction	Insulin glargine
NN1436-4477/701003	799406	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4477/701007	843701	SAE	Acute myocardial infarction	Insulin glargine
NN1436-4477/712004	835905	SAE	Diverticulitis	Insulin glargine
NN1436-4477/712004	835905	SAE	Vomiting	Insulin glargine
NN1436-4477/801008	811444	SAE	COVID-19	Insulin glargine
NN1436-4477/801008	822949	SAE	Acute myocardial infarction	Insulin glargine
NN1436-4477/802003	830247	SAE	Angina pectoris	Insulin icodec
NN1436-4477/802003	830247	SAE	Coronary artery disease	Insulin icodec
NN1436-4477/803008	861196	SAE	Iliac artery stenosis	Insulin glargine
NN1436-4477/804004	863607	SAE	Erysipelas	Insulin icodec
NN1436-4477/804004	892519	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4477/851001	837216	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4477/851001	846898	SAE	Atrial thrombosis	Insulin icodec
NN1436-4477/851001	846898	SAE	Cardiac failure	Insulin icodec
NN1436-4477/851002	909047	SAE	Osteoarthritis	Insulin icodec
NN1436-4477/858010	863611	SAE	Osteoarthritis	Insulin glargine
NN1436-4477/858011	835507	SAE	Cellulitis	Insulin icodec
NN1436-4477/858011	835507	SAE	Osteomyelitis	Insulin icodec
NN1436-4477/901013	821089	SAE	Fibula fracture	Insulin icodec
NN1436-4477/903005	906223	SAE	Hip fracture	Insulin icodec
NN1436-4477/904018	858220	SAE	Chronic hepatitis C	Insulin glargine
NN1436-4477/951007	895639	SAE	Angina unstable	Insulin glargine
NN1436-4477/951007	895639	SAE	Coronary artery disease	Insulin glargine
NN1436-4477/953002	878306	SAE	Cataract	Insulin icodec
NN1436-4477/953006	898750	SAE	Myxoid cyst	Insulin icodec
NN1436-4477/962006	851239	SAE	Cataract	Insulin glargine
ONWARDS 2				
NN1436-4478/102002	833878	SAE	Pneumonia	Insulin icodec
NN1436-4478/102002	833878	SAE	Respiratory failure	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4478/206001	842939	SAE	Myocardial infarction	Insulin icodec
NN1436-4478/206002	888007	SAE	Retinal vein occlusion	Insulin icodec
NN1436-4478/207007	837505	SAE	Tibia fracture	Insulin degludec
NN1436-4478/207010	892502	SAE	Arthritis	Insulin degludec
NN1436-4478/211002	819095	SAE	Pancreatic pseudocyst	Insulin degludec
NN1436-4478/215008	838242	SAE	Colon cancer stage II	Insulin degludec
NN1436-4478/218002	842948	SAE	Thalamic infarction	Insulin icodec
NN1436-4478/301003	838897	SAE	Gastroenteritis	Insulin icodec
NN1436-4478/301011	874513	SAE	Herpes zoster	Insulin degludec
NN1436-4478/303002	830266	SAE	Intervertebral disc protrusion	Insulin icodec
NN1436-4478/303002	877791	SAE	Paraspinal abscess	Insulin icodec
NN1436-4478/303002	884370	SAE	Pulmonary embolism	Insulin icodec
NN1436-4478/303004	858216	SAE	Pneumonia	Insulin icodec
NN1436-4478/303011	834248	SAE	Inappropriate antidiuretic hormone secretion	Insulin degludec
NN1436-4478/306007	829907	SAE	Anaemia	Insulin icodec
NN1436-4478/306007	849138	SAE	Anaemia	Insulin icodec
NN1436-4478/306007	850483	SAE	Urethral stenosis	Insulin icodec
NN1436-4478/306007	850483	SAE	Urinary tract infection	Insulin icodec
NN1436-4478/306007	875861	SAE	Anaemia	Insulin icodec
NN1436-4478/401002	805620	SAE	Hyperglycaemia	Insulin degludec
NN1436-4478/401002	842547	SAE	Vulval abscess	Insulin degludec
NN1436-4478/401002	842601	SAE	Adrenocortical insufficiency acute	Insulin degludec
NN1436-4478/401002	842601	SAE	Campylobacter gastroenteritis	Insulin degludec
NN1436-4478/401002	866909	SAE	Adrenocortical insufficiency acute	Insulin degludec
NN1436-4478/401003	859155	SAE	Coronary artery disease	Insulin icodec
NN1436-4478/403002	847271	SAE	Arthritis	Insulin degludec
NN1436-4478/403008	842954	SAE	Hand fracture	Insulin icodec
NN1436-4478/500002	820889	SAE	Intervertebral disc disorder	Insulin icodec
NN1436-4478/500003	832649	SAE	Cataract	Insulin icodec
NN1436-4478/503003	827804	SAE	Soft tissue infection	Insulin degludec
NN1436-4478/503003	827804	SAE	Toe amputation	Insulin degludec
NN1436-4478/504007	863635	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4478/601012	877163	SAE	Cerebral infarction	Insulin degludec
NN1436-4478/601015	901394	SAE	Coronary artery disease	Insulin icodec
NN1436-4478/700006	876159	SAE	Sciatica	Insulin degludec
NN1436-4478/705004	844880	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4478/803001	847679	SAE	Gastric cancer	Insulin icodec
NN1436-4478/803010	821972	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4478/807004	860390	SAE, SUSAR	Chronic myeloid leukaemia	Insulin icodec
NN1436-4478/807010	831547	SAE	Polymyalgia rheumatica	Insulin icodec
NN1436-4478/808007	820674	SAE	Peritonsillar abscess	Insulin degludec
NN1436-4478/901023	872919	SAE	Gastric dysplasia	Insulin degludec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4478/904001	827806	SAE	Acute myocardial infarction	Insulin degludec
ONWARDS 3				
NN1436-4479/106001	834588	SAE	Intervertebral disc protrusion	Insulin degludec
NN1436-4479/106002	866807	SAE	Diabetic neuropathy	Insulin degludec
NN1436-4479/106011	862526	SAE	Haemorrhoids	Insulin icodec
NN1436-4479/107005	863980	SAE	Renal colic	Insulin degludec
NN1436-4479/202009	884608	SAE	COVID-19 pneumonia	Insulin degludec
NN1436-4479/204007	853439	SAE	Erysipelas	Insulin degludec
NN1436-4479/307003	888004	SAE	Pneumonia	Insulin degludec
NN1436-4479/315013	891979	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4479/315013	891979	SAE	Cystitis	Insulin icodec
NN1436-4479/315013	891979	SAE	Escherichia bacteraemia	Insulin icodec
NN1436-4479/402030	915588	SAE	Transient ischaemic attack	Insulin icodec
NN1436-4479/402033	926076	SAE	Limb injury	Insulin degludec
NN1436-4479/504001	919312	SAE	Aortic arteriosclerosis	Insulin degludec
NN1436-4479/504010	896137	SAE	Hypoglycaemia	Insulin degludec
NN1436-4479/601003	875872	SAE	Fall	Insulin degludec
NN1436-4479/601003	875872	SAE	Haematoma	Insulin degludec
NN1436-4479/601005	891961	SAE	Asthenia	Insulin icodec
NN1436-4479/601005	891961	SAE	Cardiac failure	Insulin icodec
NN1436-4479/714001	884613	SAE	COVID-19	Insulin icodec
NN1436-4479/801001	867733	SAE	Cellulitis	Insulin degludec
NN1436-4479/801009	895641	SAE	Umbilical hernia	Insulin degludec
NN1436-4479/801012	900559	SAE	Urosepsis	Insulin degludec
NN1436-4479/805001	890001	SAE	Chest discomfort	Insulin icodec
NN1436-4479/805001	890001	SAE	Dyspnoea	Insulin icodec
NN1436-4479/853004	864000	SAE	Gastritis	Insulin degludec
NN1436-4479/904003	880968	SAE	Ureterolithiasis	Insulin icodec
NN1436-4479/904007	896109	SAE	Procedural complication	Insulin icodec
NN1436-4479/951016	879671	SAE	Influenza	Insulin icodec
ONWARDS 4				
NN1436-4480/101012	873553	SAE	Pneumonia	Insulin icodec
NN1436-4480/104002	831550	SAE	Bacteraemia	Insulin icodec
NN1436-4480/104005	838252	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4480/105005	878641	SAE	Cataract	Insulin glargine
NN1436-4480/107002	844839	SAE	Spinal compression fracture	Insulin glargine
NN1436-4480/108004	828510	SAE	Cholecystitis infective	Insulin icodec
NN1436-4480/109001	874975	SAE	Back pain	Insulin icodec
NN1436-4480/201009	894717	SAE	Hypoglycaemia	Insulin icodec
NN1436-4480/203024	870943	SAE	Myocardial ischaemia	Insulin icodec
NN1436-4480/301008	893782	SAE, SUSAR	Coronary artery disease	Insulin glargine
NN1436-4480/302001	870085	SAE	COVID-19	Insulin icodec
NN1436-4480/304004	851351	SAE	Renal colic	Insulin glargine
NN1436-4480/305010	865178	SAE	COVID-19 pneumonia	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4480/306007	891492	SAE	COVID-19	Insulin glargine
NN1436-4480/309007	874966	SAE	Carpal tunnel syndrome	Insulin glargine
NN1436-4480/311006	838561	SAE	Hypoglycaemic coma	Insulin glargine
NN1436-4480/311010	886031	SAE	Coronary artery disease	Insulin glargine
NN1436-4480/311012	878289	SAE	Coronavirus infection	Insulin glargine
NN1436-4480/311012	890605	SAE	Coronavirus infection	Insulin glargine
NN1436-4480/311015	897302	SAE	Osteomyelitis	Insulin icodec
NN1436-4480/311015	897302	SAE	Peripheral artery stenosis	Insulin icodec
NN1436-4480/311015	897302	SAE	Peripheral artery stenosis	Insulin icodec
NN1436-4480/311015	897302	SAE	Peripheral artery stenosis	Insulin icodec
NN1436-4480/311015	897302	SAE	Sepsis	Insulin icodec
NN1436-4480/311015	897302	SAE	Skin ulcer	Insulin icodec
NN1436-4480/311015	902243	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4480/311016	877161	SAE	COVID-19 pneumonia	Insulin glargine
NN1436-4480/406001	867731	SAE	Hemiparesis	Insulin glargine
NN1436-4480/406001	886747	SAE	Angina pectoris	Insulin glargine
NN1436-4480/411001	883475	SAE	Osteoarthritis	Insulin icodec
NN1436-4480/414002	861194	SAE	Diabetic foot infection	Insulin icodec
NN1436-4480/416006	867730	SAE	Angina pectoris	Insulin icodec
NN1436-4480/416010	887995	SAE	Depression	Insulin glargine
NN1436-4480/416011	898259	SAE	Fall	Insulin icodec
NN1436-4480/416011	898259	SAE	Subdural haematoma	Insulin icodec
NN1436-4480/416011	903867	SAE	Mental status changes	Insulin icodec
NN1436-4480/423002	894257	SAE	Acute myocardial infarction	Insulin glargine
NN1436-4480/423004	858223	SAE	Cerebrovascular accident	Insulin glargine
NN1436-4480/425002	882457	SAE	Post procedural infection	Insulin glargine
NN1436-4480/427010	891084	SAE	Thermal burn	Insulin glargine
NN1436-4480/428004	885024	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4480/428004	885024	SAE	Coronary artery disease	Insulin icodec
NN1436-4480/428004	885024	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4480/430006	885425	SAE	Cardiac failure congestive	Insulin glargine
NN1436-4480/430007	876158	SAE	Pneumonia	Insulin icodec
NN1436-4480/504005	861191	SAE	Gastroenteritis	Insulin glargine
NN1436-4480/507012	872143	SAE	Myocardial infarction	Insulin icodec
NN1436-4480/510002	874541	SAE	Upper gastrointestinal haemorrhage	Insulin glargine
NN1436-4480/510003	883911	SAE	Urinary tract infection	Insulin glargine
NN1436-4480/517009	893786	SAE	Myocardial infarction	Insulin icodec
NN1436-4480/804006	880639	SAE	Cardiac failure congestive	Insulin glargine
NN1436-4480/804006	891091	SAE	Cardiac failure congestive	Insulin glargine
NN1436-4480/806006	883476	SAE	COVID-19 pneumonia	Insulin icodec
ONWARDS 5				
NN1436-4481/105006	848654	SAE	Eosinophilic oesophagitis	Insulin icodec
NN1436-4481/105008	872451	SAE	Cerebral atrophy	Insulin icodec
NN1436-4481/105008	899600	SAE	Cognitive disorder	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4481/107001	874533	SAE	Cerebrovascular accident	OD analogue
NN1436-4481/107001	874533	SAE	Hypothyroidism	OD analogue
NN1436-4481/109001	905087	SAE	Diverticulitis	OD analogue
NN1436-4481/109003	830276	SAE	Acute myocardial infarction	OD analogue
NN1436-4481/109009	840276	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4481/109009	840276	SAE	Angina pectoris	Insulin icodec
NN1436-4481/114006	930598	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4481/200006	834999	SAE	Localised oedema	Insulin icodec
NN1436-4481/200006	834999	SAE, SUSAR	Localised oedema	Insulin icodec
NN1436-4481/200006	844125	SAE	Cardiac failure	Insulin icodec
NN1436-4481/202001	846506	SAE	Hypoglycaemia	OD analogue
NN1436-4481/203005	899175	SAE	Pneumonia	Insulin icodec
NN1436-4481/203005	904009	SAE	Coronary artery disease	Insulin icodec
NN1436-4481/203005	924136	SAE	Cerebral ischaemia	Insulin icodec
NN1436-4481/204004	879673	SAE	Venous stenosis	Insulin icodec
NN1436-4481/204007	853091	SAE	Acute coronary syndrome	Insulin icodec
NN1436-4481/205003	923180	SAE	Osteochondrosis	OD analogue
NN1436-4481/205013	864457	SAE	Stress urinary incontinence	OD analogue
NN1436-4481/213001	879379	SAE	Inguinal hernia	Insulin icodec
NN1436-4481/213002	871803	SAE	Trigger finger	OD analogue
NN1436-4481/213007	855697	SAE	COVID-19	Insulin icodec
NN1436-4481/214001	891500	SAE	Myocardial ischaemia	OD analogue
NN1436-4481/402002	816718	SAE	Coronary artery stenosis	OD analogue
NN1436-4481/402018	938571	SAE	Tendon rupture	Insulin icodec
NN1436-4481/408001	837863	SAE	Cholelithiasis	Insulin icodec
NN1436-4481/408001	837863	SAE	Post procedural complication	Insulin icodec
NN1436-4481/408002	901005	SAE	Cholelithiasis	Insulin icodec
NN1436-4481/408005	907271	SAE	Coronary artery disease	Insulin icodec
NN1436-4481/410010	860385	SAE	Intracranial pressure increased	Insulin icodec
NN1436-4481/520005	918859	SAE	Transient ischaemic attack	Insulin icodec
NN1436-4481/521010	817147	SAE	Coronary artery disease	OD analogue
NN1436-4481/523004	843284	SAE	Appendicitis	Insulin icodec
NN1436-4481/529001	841757	SAE	Hyperkalaemia	OD analogue
NN1436-4481/529001	841757	SAE	Hypoglycaemia	OD analogue
NN1436-4481/534001	898821	SAE	Cerebral artery embolism	OD analogue
NN1436-4481/537001	860362	SAE	Vertigo positional	Insulin icodec
NN1436-4481/547009	829974	SAE	Lumbar radiculopathy	OD analogue
NN1436-4481/547009	829974	SAE	Systemic inflammatory response syndrome	OD analogue
NN1436-4481/547009	872838	SAE	Hypertensive urgency	OD analogue
NN1436-4481/547009	872838	SAE	Pain	OD analogue
NN1436-4481/547009	905433	SAE	Hypotension	OD analogue
NN1436-4481/547009	905433	SAE	Lactic acidosis	OD analogue
NN1436-4481/547009	929980	SAE	Non-cardiac chest pain	OD analogue
NN1436-4481/550002	847734	SAE	COVID-19	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4481/551003	884597	SAE	Hepatic enzyme increased	Insulin icodec
NN1436-4481/551003	894743	SAE	Malnutrition	Insulin icodec
NN1436-4481/551003	904385	SAE	Sepsis	Insulin icodec
NN1436-4481/553001	841762	SAE	Acute respiratory failure	Insulin icodec
NN1436-4481/553001	841762	SAE	COVID-19	Insulin icodec
NN1436-4481/553005	840278	SAE	Cardiac failure congestive	Insulin icodec
NN1436-4481/553005	845237	SAE	Bronchitis	Insulin icodec
NN1436-4481/553005	896106	SAE	Wound infection	Insulin icodec
NN1436-4481/553008	823561	SAE	Small intestinal obstruction	OD analogue
NN1436-4481/557002	869583	SAE	Sweat gland infection	OD analogue
NN1436-4481/559005	830281	SAE	Cholecystitis infective	OD analogue
NN1436-4481/571005	840280	SAE	Nephrolithiasis	OD analogue
NN1436-4481/571005	840280	SAE	Ureterolithiasis	OD analogue
NN1436-4481/577001	833468	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4481/578002	876154	SAE	Fall	OD analogue
NN1436-4481/578002	876154	SAE	Rib fracture	OD analogue
NN1436-4481/580001	911825	SAE	Urosepsis	OD analogue
NN1436-4481/593001	886695	SAE	Arthralgia	OD analogue
NN1436-4481/593001	886695	SAE	Cellulitis	OD analogue
NN1436-4481/601005	810145	SAE	Appendicitis	OD analogue
NN1436-4481/601013	851387	SAE	Post procedural inflammation	Insulin icodec
NN1436-4481/601013	871403	SAE	Amnesia	Insulin icodec
NN1436-4481/601013	871403	SAE	Hip fracture	Insulin icodec
NN1436-4481/601013	871403	SAE	Road traffic accident	Insulin icodec
NN1436-4481/601013	871403	SAE	Upper limb fracture	Insulin icodec
NN1436-4481/602025	902221	SAE	White matter lesion	OD analogue
NN1436-4481/603003	910148	SAE	Ankle fracture	OD analogue
NN1436-4481/607006	851827	SAE	Rheumatoid arthritis	OD analogue
NN1436-4481/607018	844124	SAE	Peritonsillar abscess	Insulin icodec
NN1436-4481/607019	876771	SAE	Benign prostatic hyperplasia	OD analogue
NN1436-4481/607020	904635	SAE	Ileus	OD analogue
NN1436-4481/610003	875852	SAE	Skin ulcer	OD analogue
NN1436-4481/612006	926621	SAE	Herpes zoster infection neurological	OD analogue
NN1436-4481/612010	904294	SAE	Femoral neck fracture	Insulin icodec
NN1436-4481/703005	871395	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4481/703008	846512	SAE	Peripheral swelling	OD analogue
NN1436-4481/704001	824282	SAE	Osteoarthritis	OD analogue
NN1436-4481/704001	880964	SAE	Coronary artery disease	OD analogue
NN1436-4481/704001	880964	SAE	Periprocedural myocardial infarction	OD analogue
NN1436-4481/705009	896564	SAE	Drug intolerance	Insulin icodec
NN1436-4481/707002	809774	SAE	Coronary artery disease	OD analogue
NN1436-4481/707002	817873	SAE	Pulmonary mass	OD analogue
NN1436-4481/707011	857048	SAE	Gastrointestinal haemorrhage	OD analogue

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4481/707011	857048	SAE	Ischaemic stroke	OD analogue
NN1436-4481/709004	857350	SAE	Cardiac pacemaker replacement	Insulin icodec
NN1436-4481/709015	846006	SAE	Coronary artery disease	OD analogue
NN1436-4481/712008	823090	SAE	Pneumonia	Insulin icodec
NN1436-4481/712008	875343	SAE	Cardiac failure	Insulin icodec
NN1436-4481/801018	866813	SAE	Ankle fracture	OD analogue
NN1436-4481/802005	914584	SAE	Bile duct stone	OD analogue
NN1436-4481/807005	882760	SAE	Myocardial infarction	OD analogue
NN1436-4481/812005	928288	SAE	Post procedural haematuria	Insulin icodec
NN1436-4481/812012	832336	SAE	Anaemia	Insulin icodec
NN1436-4481/812012	832336	SAE	Gastric ulcer	Insulin icodec
NN1436-4481/812012	883874	SAE	Acute coronary syndrome	Insulin icodec
NN1436-4481/812013	883908	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4481/814005	952833	SAE	Hypoglycaemic unconsciousness	Insulin icodec
NN1436-4481/815001	831188	SAE	Acute myocardial infarction	Insulin icodec
NN1436-4481/815001	836781	SAE	Diarrhoea	Insulin icodec
NN1436-4481/815001	836781	SAE	Vomiting	Insulin icodec
NN1436-4481/815001	851328	SAE	Abdominal discomfort	Insulin icodec
NN1436-4481/821003	854157	SAE	COVID-19 pneumonia	OD analogue
NN1436-4481/829001	840551	SAE	Gout	OD analogue
NN1436-4481/835003	840286	SAE	Cardiac failure acute	OD analogue
NN1436-4481/835003	840286	SAE	Coronary artery disease	OD analogue
NN1436-4481/840001	919645	SAE	Ocular ischaemic syndrome	OD analogue
NN1436-4481/841001	822098	SAE	Device malfunction	Insulin icodec
NN1436-4481/848003	822348	SAE	Gangrene	Insulin icodec
ONWARDS 6				
NN1436-4625/201001	845823	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/201001	862489	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/201001	862493	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/252010	891068	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/254003	854193	SAE	Respiratory tract infection viral	Insulin icodec
NN1436-4625/307001	898710	SAE, SUSAR	Abortion spontaneous	Insulin icodec
NN1436-4625/401003	884343	SAE	COVID-19	Insulin degludec
NN1436-4625/408005	900640	SAE, SUSAR	Hypoglycaemic seizure	Insulin icodec
NN1436-4625/601013	881433	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/601013	881433	SAE	Vomiting	Insulin icodec
NN1436-4625/752006	894765	SAE	Lumbar hernia	Insulin degludec
NN1436-4625/753008	903082	SAE	Angina unstable	Insulin degludec
NN1436-4625/753008	903082	SAE	Myocardial ischaemia	Insulin degludec
NN1436-4625/755005	864010	SAE	Cystitis escherichia	Insulin degludec
NN1436-4625/756005	889189	SAE	Benign prostatic hyperplasia	Insulin icodec
NN1436-4625/804003	870956	SAE	Hypoglycaemic seizure	Insulin degludec
NN1436-4625/805007	907181	SAE, SUSAR	Hypoglycaemia	Insulin icodec
NN1436-4625/809006	890159	SAE	COVID-19	Insulin icodec

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4625/809006	890159	SAE	COVID-19 pneumonia	Insulin icodec
NN1436-4625/902004	858227	SAE	Haemorrhoids	Insulin degludec
NN1436-4625/902011	861200	SAE	Cardiac ablation	Insulin icodec
NN1436-4625/907004	853457	SAE, SUSAR	Obesity	Insulin degludec

3.17 Non-serious adverse events leading to treatment discontinuation

Unique subject ID	Reason(s) for narrative	Preferred term	Actual treatment
ONWARDS 1			
NN1436-4477/139003	AE leading to permanent discontinuation of trial product	Weight increased	Insulin icodec
NN1436-4477/143011	AE leading to permanent discontinuation of trial product	Weight increased	Insulin icodec
NN1436-4477/154001	AE leading to permanent discontinuation of trial product	Obesity	Insulin icodec
NN1436-4477/704003	AE leading to permanent discontinuation of trial product	Mood swings	Insulin glargine
NN1436-4477/954001	AE leading to permanent discontinuation of trial product	Glycosylated haemoglobin increased	Insulin icodec
ONWARDS 2			
NN1436-4478/220002	AE leading to permanent discontinuation of trial product	Alopecia	Insulin icodec
NN1436-4478/803018	AE leading to permanent discontinuation of trial product	Nephrotic syndrome	Insulin icodec
NN1436-4478/903007	AE leading to permanent discontinuation of trial product	Urticaria	Insulin icodec
ONWARDS 3			
NN1436-4479/201011	Adverse event leading to permanent discontinuation of trial product	Blood glucose fluctuation	Insulin icodec
NN1436-4479/801009	Adverse event leading to permanent discontinuation of trial product	Flank pain	Insulin degludec
ONWARDS 5			
NN1436-4481/203005	Adverse event leading to permanent discontinuation of trial product	Asthenia	Insulin icodec
NN1436-4481/523006	Adverse event leading to permanent discontinuation of trial product	Dehydration	Insulin icodec
NN1436-4481/547004	Adverse event leading to permanent discontinuation of trial product	Weight increased	OD analogues
NN1436-4481/802006	Adverse event leading to permanent discontinuation of trial product	Dizziness	OD analogues
ONWARDS 6			
NN1436-4625/205003	AE leading to permanent discontinuation of trial product	Insulin resistance	Insulin degludec

4 Narratives for phase 2 trials

4.1 Trial NN1436-4383:

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4383/208002	671841	SAE	Metrorrhagia	Insulin icodec
NN1436-4383/304001	657810	SAE, AE leading to premature trial product discontinuation	Coronary artery disease	Insulin glargine
NN1436-4383/401007	669025	SAE	Cerebral disorder	Insulin glargine
NN1436-4383/500007	657271	SAE, Unblinded	Concussion	Insulin glargine
NN1436-4383/500007	657271	SAE, Unblinded	Fall	Insulin glargine
NN1436-4383/602001	661879	SAE	Lower limb fracture	Insulin icodec
NN1436-4383/602004	667771	SAE, Unblinded	Device battery issue	Insulin icodec
NN1436-4383/703003	662329	SAE	Acute kidney injury	Insulin glargine
NN1436-4383/703003	662329	SAE	Anaemia	Insulin glargine
NN1436-4383/703003	662329	SAE	Azotaemia	Insulin glargine
NN1436-4383/703003	662329	SAE	Emphysematous pyelonephritis	Insulin glargine
NN1436-4383/703003	662329	SAE	Hepatosplenomegaly	Insulin glargine
NN1436-4383/703003	662329	SAE	Hydronephrosis	Insulin glargine
NN1436-4383/703003	662329	SAE	Hypomagnesaemia	Insulin glargine
NN1436-4383/703003	662329	SAE	Leukocytosis	Insulin glargine
NN1436-4383/703003	662329	SAE	Tachycardia	Insulin glargine
NN1436-4383/703003	691048	SAE	Melaena	Insulin glargine

4.2 Trial NN1436-4465

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4465/101001	678899	SAE Trial product discontinuation	Transitional cell carcinoma	Insulin icodec (titA)
NN1436-4465/104003	683392	SAE	Erysipelas	Insulin icodec (titB)
NN1436-4465/104006	689690	SAE	Knee arthroplasty	Insulin glargine
NN1436-4465/303003	675547	SAE	Choroid neoplasm	Insulin icodec (titA)
NN1436-4465/304006	680982	SAE	Angina pectoris	Insulin icodec (titA)
NN1436-4465/617001	675539	SAE	Pneumonia	Insulin glargine

4.3 Trial NN1436-4466

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4466/201008	697042	SAE	Myocardial infarction	Insulin glargine
NN1436-4466/304009	685374	SAE	Muscle abscess	Insulin icodec +loading dose
NN1436-4466/405005	684425	SAE	Fall	Insulin icodec +loading dose

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Actual treatment
NN1436-4466/405005	689691	SAE Trial product discontinuation	Acute myocardial infarction	Insulin icodec +loading dose

5 Narratives for clinical pharmacology trials

Unique subject ID	Case number	Reason(s) for narrative	Preferred term	Treatment group
NN1436-4226				
NN1436-4226/101095	680007	SAE	Craniocerebral injury	Insulin icodec 1.5 U/kg
NN1436-4226/101095	680007	SAE	Fall	Insulin icodec 1.5 U/kg
NN1436-4226/101095	680007	SAE	Skin laceration	Insulin icodec 1.5 U/kg
NN1436-4314				
NN1436-4314101027	541791	SAE	Myocardial necrosis marker increased	Not exposed (before randomization)
NN1436-4462				
NN1436-4462/101045	733527	SAE	Syncope	Not exposed
NN1436-4569				
NN1436-4569/101025	N/A	AE leading to permanent discontinuation of trial product	Rash pruritic	Insulin icodec
NN1436-4569/101033	N/A	AE leading to permanent discontinuation of trial product	Rash	Insulin icodec
NN1436-4569/101036	N/A	AE leading to permanent discontinuation of trial product	Pruritus	Insulin icodec
NN1436-4570				
NN1436-4570/101010	829592	SAE	Hypokalaemia	Insulin icodec
NN1436-4570/101011	832738	SAE, SUSAR, Withdrawal from trial	Loss of consciousness	Insulin icodec
NN1436-4570/101017	874227	SAE, SUSAR, Withdrawal from trial	Pleural effusion	Insulin icodec

There were no narrative cases in the following trials:

- NN1436-4422
- NN1436-4571
- NN1436-4572

6 Narratives for pregnancies

Unique subject ID	Case Number	Reason(s) for Narrative	Preferred Term	Actual treatment
ONWARDS 5				
NN1436-4481/575004	932089	Pregnancy	Maternal exposure during pregnancy	Insulin icodec
ONWARDS 6				
NN1436-4625/307001	898710	Pregnancy	Maternal exposure during pregnancy	Insulin icodec
NN1436-4625/631002	915402	SAE, Pregnancy	Maternal exposure during pregnancy	Insulin degludec
NN1436-4625/706006	878067	Pregnancy	Maternal exposure during pregnancy	Insulin icodec

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
10. 注目すべき安全性領域内の MedDRA 検索

ノボ ノルディスク ファーマ株式会社

Common Technical Document Summaries

NN1436 Insulin icodec

2.7.4: Appendix 7.10

MedDRA searches within safety focus areas

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Table of contents

Page

Table of contents **2**

List of abbreviations and definitions of terms **3**

1 MedDRA searches for safety focus areas in project NN1436 ..... **4**

1.1 Antibody formation leading to change in clinical effect 4
1.2 Localised amyloidosis 4
1.3 Diabetic retinopathy and maculopathy 4
1.4 Hyperglycaemia incl. diabetic ketoacidosis 4
1.5 Hypersensitivity 4
1.6 Hypokalaemia 4
1.7 Injection site reactions 5
1.8 Lipodystrophy 5
1.9 Medication error incl. misuse and abuse 5
1.10 Other microvascular diabetic complications 5
1.11 Neoplasm 5
1.12 Clinically meaningful peripheral oedema 6
1.13 Rare events 6
1.14 Suspected transmission of infectious agents 6

List of abbreviations and definitions of terms

AE	adverse event
HLT	high level term
MedDRA	Medical Dictionary for Regulatory Activities
NEC	not elsewhere classified
NNMQ	Novo Nordisk MedDRA query
PT	preferred term
SMQ	standardised MedDRA query
SOC	system organ class

1 MedDRA searches for safety focus areas in project NN1436

The MedDRA search strings in this document (ordered alphabetically) were used for the NN1436 submission documents. The same search strings were used for the ONWARDS 1-6 clinical trial reports. The MedDRA version used was 24.1.

1.1 Antibody formation leading to change in clinical effect

Custom query (NNMQ Antibody Insulins):

- Single PTs (non-insulin specific): Antibody test, Antibody test abnormal, Antibody test positive, Autoantibody positive, Autoantibody test, Drug specific antibody present, Inhibiting antibodies, Neutralising antibodies, Neutralising antibodies positive, Non-neutralising antibodies positive, Drug specific antibody, Treatment boosted antibody positive
- Single PTs (insulin specific): Anti-insulin antibody, Anti-insulin antibody increased, Anti-insulin antibody positive

1.2 Localised amyloidosis

Single PTs:

- Cutaneous amyloidosis
- Amyloidosis

1.3 Diabetic retinopathy and maculopathy

Custom query (NNMQ Retinal disorders and visual impairment):

- Retinal disorders (SMQ code 20000158), narrow terms only
- Visual impairment and blindness (excluding colour blindness) (HLT code 10080708), primary terms only

1.4 Hyperglycaemia incl. diabetic ketoacidosis

Custom Query (NNMQ Hyperglycaemia):

- Hyperglycaemia/new onset diabetes mellitus (SMQ code 20000041) – only narrow terms

1.5 Hypersensitivity

Custom Query (NNMQ Allergic reactions) – only narrow terms from the following SMQs:

- Anaphylactic reaction (SMQ code 20000021)
- Angioedema (SMQ code 20000024)
- Severe cutaneous adverse reactions (SMQ code 20000020)
- Anaphylactic/anaphylactoid shock conditions (SMQ code 20000071)
- Hypersensitivity (SMQ code 20000214)

1.6 Hypokalaemia

SMQ Hypokalaemia (SMQ code 20000233) - only narrow terms

1.7 Injection site reactions

Custom query (NNMQ Injection site reactions)- both primary and secondary terms from the following HLTs:

- Administration site reactions NEC (HLT code 10057196)
- Application and instillation site reactions (HLT code 10003057)
- Infusion site reactions (HLT code 10068753)
- Injection site reactions (HLT code 10022097)

1.8 Lipodystrophy

Custom query (NNMQ Lipodystrophies):

- Lipodystrophies (HLT code 10024606), including both primary and secondary PTs

1.9 Medication error incl. misuse and abuse

SMQ Medication errors (SMQ code 20000224)

Custom query (NNMQ Abuse and Misuse, used across all projects in Novo Nordisk)

- Drug abuse and dependence (SMQ code 20000101) - only narrow terms included
- Intentional product misuses (HLT code 10079157)
- Single PTs: Poisoning deliberate, Intentional dose omission, Performance enhancing product use, Completed suicide, Intentional self-injury, Suicide attempt, Assisted suicide, Suspected suicide attempt, Suspected suicide.

1.10 Other microvascular diabetic complications

Custom query (NNMQ Microvascular disease) - both primary and secondary terms of below HLTs included:

- Diabetic complications renal (HLT code 10012658)
- Diabetic complications dermal (HLT code 10062911)
- Diabetic complications neurological (HLT code 10012656)

1.11 Neoplasm

Custom query (NNMQ Neoplasm):

- Biliary neoplasms (SMQ code 20000121)
- Breast neoplasms, malignant and unspecified (SMQ code 20000149)
- Liver neoplasms, benign (incl cysts and polyps) (SMQ code 20000012)
- Liver neoplasms, malignant and unspecified (SMQ code 20000011)
- Malignancies (SMQ code 20000090)
- Malignant lymphomas (SMQ code 20000215)
- Oropharyngeal neoplasms (SMQ code 20000110)
- Ovarian neoplasms, malignant and unspecified (SMQ code 20000151)
- Premalignant disorders (SMQ code 20000085)
- Prostate neoplasms, malignant and unspecified (SMQ code 20000152)
- Skin neoplasms, malignant and unspecified (SMQ code 20000173)
- Uterine and fallopian tube neoplasms, malignant and unspecified (SMQ code 20000153)

- Neoplasms benign, malignant and unspecified (incl cysts and polyps) (SOC code 10029104) (primary and secondary terms)

1.12 Clinically meaningful peripheral oedema

Single PTs:
- Oedema peripheral
- Peripheral swelling

1.13 Rare events

Custom query (NNMQ Rare events, used across all projects in Novo Nordisk (excluding events that are included in other safety focus areas)):
- Acute pancreatitis (SMQ code 20000022) - narrow scope terms only
- Acute renal failure (SMQ code 20000003) - narrow scope terms only
- Agranulocytosis (SMQ code 20000023) - narrow scope terms only
- Cardiac arrhythmias (SMQ code 20000049) - narrow and Broad Scope Terms
- Cholestasis and jaundice of hepatic origin (SMQ code 20000009) - narrow and Broad Scope Terms
- Guillain-Barre syndrome (SMQ code 20000131) - narrow scope terms only
- Haematopoietic cytopenias affecting more than one type of blood cell (SMQ code 20000028) - narrow and broad scope terms
- Haematopoietic leukopenia (SMQ code 20000030) - narrow and broad scope terms
- Haematopoietic thrombocytopenia (SMQ code 20000031) - narrow scope terms only
- Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ code 20000013) - narrow scope terms only
- Hepatitis, non-infectious (SMQ code 20000010) - narrow and broad scope terms
- Interstitial lung disease (SMQ code 20000042) - narrow terms only
- Neuroleptic malignant syndrome (SMQ code 20000044) - narrow scope terms only
- Pseudomembranous colitis (SMQ code 20000080) - narrow scope terms only
- Retroperitoneal fibrosis (SMQ code 20000065) - narrow scope terms only
- SOCs: Congenital, familial and genetic disorders (SOC code 10010331) - contains only primary terms
- HLTs:
  - Acute and chronic pancreatitis (HLT code 10033646) - primary and secondary routed PTs
  - Glomerulonephritis and nephrotic syndrome (HLT code 10018365) - primary and secondary routed PTs
  - Nephritis NEC (HLT code 10029137) - primary and secondary routed PTs
- Single PTs: Disseminated intravascular coagulation, Multiple organ dysfunction syndrome, Hepatic lymphocytic infiltration

1.14 Suspected transmission of infectious agents

Custom query (NNMQ Transmission) – only primary terms included from the below HLTs:
- Infectious disorders carrier (HLT code 10021910)
- Infectious transmissions (HLT code 10027684)

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
11. イベント判定のための MedDRA 基本語検索式（PTQ）

ノボ ノルディスク ファーマ株式会社

Common Technical Document Summaries

NN1436 insulin icodec

2.7.4: Appendix 7.11

PTQs (MedDRA preferred terms) for event adjudication

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

1 Preferred term query for adjudication

The Preferred term query (PTQ), a pre-defined list of MedDRA PTs, used to screen all reported AEs for events in scope for adjudication during the ONWARDS 1-6 trials consist of MedDRA SMQs. The latest MedDRA version used was 24.1.

2 Acute coronary syndrome

Myocardial infarction (SMQ), narrow terms only.

3 Cerebrovascular events

The following SMQs, narrow terms only:

- Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (SMQ)
- Haemorrhagic central nervous system vascular conditions (SMQ)
- Ischaemic central nervous system vascular conditions (SMQ)

4 Heart Failure

Cardiac failure (SMQ), narrow terms only.

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
12. 進行中の試験（延長パートを含む）の安全性データ

ノボ ノルディスク ファーマ株式会社

詳細は Module 5.3.5.4、Safety data from extension trials and ongoing trials に示した。

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
13. データベースロック後に更新された安全性データ

ノボ ノルディスク ファーマ株式会社

詳細は Module 5.3.5.4、Safety data from post-DBL safety updates に示した。

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
14. 重篤な有害事象及び治験薬の投与中止に至った有害事象（試験別）

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.14.1 Serious adverse events by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set....2
7.14.2 Serious adverse events by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set....5
7.14.3 Serious adverse events by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set....7
7.14.4 Serious adverse events by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set....9
7.14.5 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 1 (main part) - main-on-treatment - summary - safety analysis set....10
7.14.6 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 2 - on-treatment - summary - safety analysis set....11
7.14.7 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 4 - on-treatment - summary - safety analysis set....12
7.14.8 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 6 (main part) - main-on-treatment - summary - safety analysis set....13

7.14 Serious adverse events and adverse events leading to discontinuation by trial

7.14.1 Serious adverse events by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	51	(10.4)	74	15.16	49	(10.0)	73	14.99
Cardiac disorders	18	(3.7)	28	5.74	10	(2.0)	13	2.67
Atrial fibrillation	5	(1.0)	5	1.02	2	(0.4)	2	0.41
Coronary artery disease	4	(0.8)	4	0.82	1	(0.2)	1	0.21
Myocardial infarction	3	(0.6)	3	0.61	2	(0.4)	2	0.41
Acute coronary syndrome	2	(0.4)	2	0.41	0			
Acute myocardial infarction	2	(0.4)	2	0.41	4	(0.8)	4	0.82
Angina unstable	2	(0.4)	2	0.41	1	(0.2)	1	0.21
Cardiac failure	2	(0.4)	2	0.41	0			
Coronary artery occlusion	2	(0.4)	2	0.41	0			
Angina pectoris	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Atrial flutter	1	(0.2)	1	0.20	0			
Atrial thrombosis	1	(0.2)	1	0.20	0			
Cardiac failure congestive	1	(0.2)	1	0.20	0			
Chronic coronary syndrome	1	(0.2)	1	0.20	0			
Sinus tachycardia	1	(0.2)	1	0.20	0			
Atrioventricular block complete	0				1	(0.2)	1	0.21
Left ventricular dysfunction	0				1	(0.2)	1	0.21
Infections and infestations	11	(2.2)	15	3.07	18	(3.7)	19	3.90
COVID-19	4	(0.8)	4	0.82	2	(0.4)	2	0.41
COVID-19 pneumonia	4	(0.8)	4	0.82	2	(0.4)	2	0.41
Pneumonia	2	(0.4)	2	0.41	1	(0.2)	1	0.21
Bronchitis	1	(0.2)	1	0.20	0			
Cellulitis	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Erysipelas	1	(0.2)	1	0.20	0			
Osteomyelitis	1	(0.2)	1	0.20	0			
Respiratory syncytial virus infection	1	(0.2)	1	0.20	0			
Urinary tract infection	0				2	(0.4)	2	0.41
Anal abscess	0				1	(0.2)	1	0.21
Chronic hepatitis C	0				1	(0.2)	1	0.21
Clostridium difficile infection	0				1	(0.2)	1	0.21
Coronavirus infection	0				1	(0.2)	1	0.21
Diverticulitis	0				1	(0.2)	1	0.21
Empyema	0				1	(0.2)	1	0.21
Endophthalmitis	0				1	(0.2)	1	0.21
Laryngitis	0				1	(0.2)	1	0.21
Otitis media acute	0				1	(0.2)	1	0.21
Post procedural infection	0				1	(0.2)	1	0.21
Sepsis	0				1	(0.2)	1	0.21
Injury, poisoning and procedural complications	4	(0.8)	4	0.82	6	(1.2)	6	1.23
Fibula fracture	1	(0.2)	1	0.20	0			
Hip fracture	1	(0.2)	1	0.20	0			
Meniscus injury	1	(0.2)	1	0.20	0			
Post procedural haemorrhage	1	(0.2)	1	0.20	0			
Deafness traumatic	0				1	(0.2)	1	0.21
Endotracheal intubation complication	0				1	(0.2)	1	0.21
Lower limb fracture	0				1	(0.2)	1	0.21
Post procedural stroke	0				1	(0.2)	1	0.21
Radius fracture	0				1	(0.2)	1	0.21
Rib fracture	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IGlar U100.

Serious adverse events by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Vascular disorders	4	(0.8)	5	1.02	2	(0.4)	2	0.41
Hypertensive urgency	1	(0.2)	1	0.20	0			
Peripheral arterial occlusive disease	1	(0.2)	1	0.20	0			
Peripheral artery occlusion	1	(0.2)	1	0.20	0			
Peripheral artery stenosis	1	(0.2)	2	0.41	0			
Brachiocephalic arteriosclerosis	0				1	(0.2)	1	0.21
Iliac artery stenosis	0				1	(0.2)	1	0.21
Musculoskeletal and connective tissue disorders	3	(0.6)	3	0.61	3	(0.6)	3	0.62
Back pain	1	(0.2)	1	0.20	0			
Osteoarthritis	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Plantar fasciitis	1	(0.2)	1	0.20	0			
Spinal pain	0				2	(0.4)	2	0.41
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	3	(0.6)	4	0.82	3	(0.6)	5	1.03
Basal cell carcinoma	1	(0.2)	1	0.20	0			
Glioblastoma multiforme	1	(0.2)	1	0.20	0			
Metastases to liver	1	(0.2)	1	0.20	0			
Pancreatic neoplasm	1	(0.2)	1	0.20	0			
Colon cancer	0				1	(0.2)	1	0.21
Hepatocellular carcinoma	0				1	(0.2)	1	0.21
Malignant melanoma in situ	0				1	(0.2)	1	0.21
Ovarian cancer metastatic	0				1	(0.2)	1	0.21
Renal cell carcinoma	0				1	(0.2)	1	0.21
Nervous system disorders	3	(0.6)	3	0.61	2	(0.4)	2	0.41
Cerebral haemorrhage	1	(0.2)	1	0.20	0			
Cervical radiculopathy	1	(0.2)	1	0.20	0			
Transient ischaemic attack	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Thrombotic stroke	0				1	(0.2)	1	0.21
Eye disorders	2	(0.4)	2	0.41	2	(0.4)	2	0.41
Cataract	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Diplopia	1	(0.2)	1	0.20	0			
Diabetic retinal oedema	0				1	(0.2)	1	0.21
Reproductive system and breast disorders	2	(0.4)	2	0.41	0			
Benign prostatic hyperplasia	1	(0.2)	1	0.20	0			
Uterine prolapse	1	(0.2)	1	0.20	0			
Respiratory, thoracic and mediastinal disorders	2	(0.4)	2	0.41	1	(0.2)	3	0.62
Acute respiratory failure	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Interstitial lung disease	1	(0.2)	1	0.20	0			
Acute pulmonary oedema	0				1	(0.2)	1	0.21
Pleural effusion	0				1	(0.2)	1	0.21
Blood and lymphatic system disorders	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Anaemia	1	(0.2)	1	0.20	0			
Blood loss anaemia	0				1	(0.2)	1	0.21
Congenital, familial and genetic disorders	1	(0.2)	1	0.20	0			
Hydrocele	1	(0.2)	1	0.20	0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IGlar U100.

Serious adverse events by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Gastrointestinal disorders	1	(0.2)	1	0.20	4	(0.8)	6	1.23
Colitis ischaemic	1	(0.2)	1	0.20	0			
Inguinal hernia	0				1	(0.2)	2	0.41
Large intestine polyp	0				1	(0.2)	1	0.21
Pancreatitis acute	0				1	(0.2)	1	0.21
Umbilical hernia	0				1	(0.2)	1	0.21
Vomiting	0				1	(0.2)	1	0.21
Metabolism and nutrition disorders	1	(0.2)	1	0.20	0			
Hyperkalaemia	1	(0.2)	1	0.20	0			
Renal and urinary disorders	1	(0.2)	1	0.20	3	(0.6)	3	0.62
Ureterolithiasis	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Acute kidney injury	0				1	(0.2)	1	0.21
Urinary tract obstruction	0				1	(0.2)	1	0.21
Skin and subcutaneous tissue disorders	1	(0.2)	1	0.20	0			
Myxoid cyst	1	(0.2)	1	0.20	0			
General disorders and administration site conditions	0				2	(0.4)	2	0.41
Death	0				1	(0.2)	1	0.21
Non-cardiac chest pain	0				1	(0.2)	1	0.21
Ear and labyrinth disorders	0				1	(0.2)	1	0.21
Presbyacusis	0				1	(0.2)	1	0.21
Hepatobiliary disorders	0				1	(0.2)	1	0.21
Hepatic cirrhosis	0				1	(0.2)	1	0.21
Immune system disorders	0				1	(0.2)	2	0.41
Immunisation reaction	0				1	(0.2)	2	0.41
Investigations	0				1	(0.2)	1	0.21
Cardiac stress test abnormal	0				1	(0.2)	1	0.21
Surgical and medical procedures	0				1	(0.2)	1	0.21
Removal of foreign body	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IGlar U100.

7.14.2 Serious adverse events by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	22	(8.4)	31	19.80	16	(6.1)	22	14.11
Infections and infestations	9	(3.4)	9	5.75	4	(1.5)	5	3.21
COVID-19	2	(0.8)	2	1.28	0			
COVID-19 pneumonia	2	(0.8)	2	1.28	0			
Pneumonia	2	(0.8)	2	1.28	0			
Gastroenteritis	1	(0.4)	1	0.64	0			
Paraspinal abscess	1	(0.4)	1	0.64	0			
Urinary tract infection	1	(0.4)	1	0.64	0			
Campylobacter gastroenteritis	0				1	(0.4)	1	0.64
Herpes zoster	0				1	(0.4)	1	0.64
Peritonsillar abscess	0				1	(0.4)	1	0.64
Soft tissue infection	0				1	(0.4)	1	0.64
Vulval abscess	0				1	(0.4)	1	0.64
Cardiac disorders	4	(1.5)	4	2.55	1	(0.4)	1	0.64
Acute myocardial infarction	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Coronary artery disease	1	(0.4)	1	0.64	0			
Myocardial infarction	1	(0.4)	1	0.64	0			
Supraventricular tachycardia	1	(0.4)	1	0.64	0			
Musculoskeletal and connective tissue disorders	3	(1.1)	3	1.92	2	(0.8)	2	1.28
Intervertebral disc disorder	1	(0.4)	1	0.64	0			
Intervertebral disc protrusion	1	(0.4)	1	0.64	0			
Polymyalgia rheumatica	1	(0.4)	1	0.64	0			
Arthritis	0				2	(0.8)	2	1.28
Respiratory, thoracic and mediastinal disorders	3	(1.1)	3	1.92	0			
Acute respiratory failure	1	(0.4)	1	0.64	0			
Pulmonary embolism	1	(0.4)	1	0.64	0			
Respiratory failure	1	(0.4)	1	0.64	0			
Eye disorders	2	(0.8)	2	1.28	0			
Cataract	1	(0.4)	1	0.64	0			
Retinal vein occlusion	1	(0.4)	1	0.64	0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2	(0.8)	2	1.28	2	(0.8)	2	1.28
Chronic myeloid leukaemia	1	(0.4)	1	0.64	0			
Gastric cancer	1	(0.4)	1	0.64	0			
Colon cancer stage II	0				1	(0.4)	1	0.64
Pancreatic carcinoma metastatic	0				1	(0.4)	1	0.64
Nervous system disorders	2	(0.8)	2	1.28	3	(1.1)	3	1.92
Syncope	1	(0.4)	1	0.64	0			
Thalamic infarction	1	(0.4)	1	0.64	0			
Cerebral infarction	0				1	(0.4)	1	0.64
Sciatica	0				1	(0.4)	1	0.64
Thrombotic stroke	0				1	(0.4)	1	0.64
Blood and lymphatic system disorders	1	(0.4)	3	1.92	0			
Anaemia	1	(0.4)	3	1.92	0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IDeg.

Serious adverse events by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Immune system disorders	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Anaphylactic reaction	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Injury, poisoning and procedural complications	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Hand fracture	1	(0.4)	1	0.64	0			
Tibia fracture	0				1	(0.4)	1	0.64
Renal and urinary disorders	1	(0.4)	1	0.64	0			
Urethral stenosis	1	(0.4)	1	0.64	0			
Endocrine disorders	0				2	(0.8)	3	1.92
Adrenocortical insufficiency acute	0				1	(0.4)	2	1.28
Inappropriate antidiuretic hormone secretion	0				1	(0.4)	1	0.64
Gastrointestinal disorders	0				2	(0.8)	2	1.28
Gastric dysplasia	0				1	(0.4)	1	0.64
Pancreatic pseudocyst	0				1	(0.4)	1	0.64
Metabolism and nutrition disorders	0				1	(0.4)	1	0.64
Hyperglycaemia	0				1	(0.4)	1	0.64
Surgical and medical procedures	0				1	(0.4)	1	0.64
Toe amputation	0				1	(0.4)	1	0.64

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IDeg.

7.14.3 Serious adverse events by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	22	(7.6)	35	20.59	25	(8.6)	33	19.41
Infections and infestations	11	(3.8)	12	7.06	6	(2.1)	7	4.12
COVID-19 pneumonia	4	(1.4)	4	2.35	1	(0.3)	1	0.59
Pneumonia	2	(0.7)	2	1.18	0			
Bacteraemia	1	(0.3)	1	0.59	0			
Cholecystitis infective	1	(0.3)	1	0.59	0			
COVID-19	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Diabetic foot infection	1	(0.3)	1	0.59	0			
Osteomyelitis	1	(0.3)	1	0.59	0			
Sepsis	1	(0.3)	1	0.59	0			
Coronavirus infection	0				1	(0.3)	2	1.18
Gastroenteritis	0				1	(0.3)	1	0.59
Post procedural infection	0				1	(0.3)	1	0.59
Urinary tract infection	0				1	(0.3)	1	0.59
Cardiac disorders	5	(1.7)	6	3.53	6	(2.1)	7	4.12
Myocardial infarction	2	(0.7)	2	1.18	0			
Acute myocardial infarction	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Angina pectoris	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Coronary artery disease	1	(0.3)	1	0.59	2	(0.7)	2	1.18
Myocardial ischaemia	1	(0.3)	1	0.59	0			
Cardiac failure congestive	0				2	(0.7)	3	1.76
Metabolism and nutrition disorders	3	(1.0)	3	1.76	1	(0.3)	1	0.59
Hypoglycaemia	3	(1.0)	3	1.76	0			
Hyperglycaemia	0				1	(0.3)	1	0.59
Musculoskeletal and connective tissue disorders	2	(0.7)	2	1.18	0			
Back pain	1	(0.3)	1	0.59	0			
Osteoarthritis	1	(0.3)	1	0.59	0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2	(0.7)	2	1.18	2	(0.7)	3	1.76
Pancreatic neoplasm	1	(0.3)	1	0.59	0			
Small cell lung cancer	1	(0.3)	1	0.59	0			
Lung adenocarcinoma	0				1	(0.3)	1	0.59
Small intestine neuroendocrine tumour	0				1	(0.3)	1	0.59
Uterine cancer	0				1	(0.3)	1	0.59
General disorders and administration site conditions	1	(0.3)	1	0.59	0			
Multiple organ dysfunction syndrome	1	(0.3)	1	0.59	0			
Injury, poisoning and procedural complications	1	(0.3)	2	1.18	3	(1.0)	3	1.76
Fall	1	(0.3)	1	0.59	0			
Subdural haematoma	1	(0.3)	1	0.59	0			
Overdose	0				1	(0.3)	1	0.59
Spinal compression fracture	0				1	(0.3)	1	0.59
Thermal burn	0				1	(0.3)	1	0.59

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IGlar U100.

Serious adverse events by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Psychiatric disorders	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Mental status changes	1	(0.3)	1	0.59	0			
Depression	0				1	(0.3)	1	0.59
Renal and urinary disorders	1	(0.3)	2	1.18	1	(0.3)	1	0.59
Acute kidney injury	1	(0.3)	1	0.59	0			
Chronic kidney disease	1	(0.3)	1	0.59	0			
Renal colic	0				1	(0.3)	1	0.59
Skin and subcutaneous tissue disorders	1	(0.3)	1	0.59	0			
Skin ulcer	1	(0.3)	1	0.59	0			
Vascular disorders	1	(0.3)	3	1.76	0			
Peripheral artery stenosis	1	(0.3)	3	1.76	0			
Nervous system disorders	0				4	(1.4)	4	2.35
Carpal tunnel syndrome	0				1	(0.3)	1	0.59
Cerebrovascular accident	0				1	(0.3)	1	0.59
Hemiparesis	0				1	(0.3)	1	0.59
Hypoglycaemic coma	0				1	(0.3)	1	0.59
Eye disorders	0				3	(1.0)	4	2.35
Diabetic retinal oedema	0				2	(0.7)	3	1.76
Cataract	0				1	(0.3)	1	0.59
Gastrointestinal disorders	0				2	(0.7)	2	1.18
Gastrointestinal haemorrhage	0				1	(0.3)	1	0.59
Upper gastrointestinal haemorrhage	0				1	(0.3)	1	0.59

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IGlar U100.

7.14.4 Serious adverse events by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	11	(3.8)	15	10.47	7	(2.4)	9	6.22
Metabolism and nutrition disorders	4	(1.4)	6	4.19	1	(0.3)	1	0.69
Hypoglycaemia	4	(1.4)	6	4.19	0			
Obesity	0				1	(0.3)	1	0.69
Infections and infestations	2	(0.7)	3	2.09	2	(0.7)	2	1.38
COVID-19	1	(0.3)	1	0.70	1	(0.3)	1	0.69
COVID-19 pneumonia	1	(0.3)	1	0.70	0			
Respiratory tract infection viral	1	(0.3)	1	0.70	0			
Cystitis escherichia	0				1	(0.3)	1	0.69
Nervous system disorders	2	(0.7)	2	1.40	1	(0.3)	1	0.69
Haemorrhage intracranial	1	(0.3)	1	0.70	0			
Hypoglycaemic seizure	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Gastrointestinal disorders	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Vomiting	1	(0.3)	1	0.70	0			
Haemorrhoids	0				1	(0.3)	1	0.69
Lumbar hernia	0				1	(0.3)	1	0.69
Injury, poisoning and procedural complications	1	(0.3)	1	0.70	0			
Product administration error	1	(0.3)	1	0.70	0			
Reproductive system and breast disorders	1	(0.3)	1	0.70	0			
Benign prostatic hyperplasia	1	(0.3)	1	0.70	0			
Surgical and medical procedures	1	(0.3)	1	0.70	0			
Cardiac ablation	1	(0.3)	1	0.70	0			
Cardiac disorders	0				1	(0.3)	2	1.38
Angina unstable	0				1	(0.3)	1	0.69
Myocardial ischaemia	0				1	(0.3)	1	0.69
Investigations	0				1	(0.3)	1	0.69
Blood glucose increased	0				1	(0.3)	1	0.69

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & AESER == "Y" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:53 - taesocpt/taessocptsumintow6sas.txt

7.14.5 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 1 (main part) - main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Events	6	(1.2)	7	1.44	4	(0.8)	4	0.82
Investigations	3	(0.6)	3	0.62	0			
Weight increased	2	(0.4)	2	0.41	0			
Glycosylated haemoglobin increased	1	(0.2)	1	0.21	0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2	(0.4)	3	0.62	0			
Glioblastoma multiforme	1	(0.2)	1	0.21	0			
Metastases to liver	1	(0.2)	1	0.21	0			
Pancreatic neoplasm	1	(0.2)	1	0.21	0			
Metabolism and nutrition disorders	1	(0.2)	1	0.21	0			
Obesity	1	(0.2)	1	0.21	0			
Cardiac disorders	0				1	(0.2)	1	0.21
Angina pectoris	0				1	(0.2)	1	0.21
General disorders and administration site conditions	0				1	(0.2)	1	0.21
Death	0				1	(0.2)	1	0.21
Injury, poisoning and procedural complications	0				1	(0.2)	1	0.21
Rib fracture	0				1	(0.2)	1	0.21
Psychiatric disorders	0				1	(0.2)	1	0.21
Mood swings	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYE), PYE: Patient years of exposure (1 PYE = 365.25 days). On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. MedDRA version 24.1. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): OTMTDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & (AACN1 == "DRUG WITHDRAWN" | (AACN1 == "DRUG INTERRUPTED" & AOUT == "FATAL")) & (ANL06FL) == "Y" & (ANELFL) == "Y"

7.14.6 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 2 - on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Events	5	(1.9)	5	3.22	3	(1.1)	3	1.96
Skin and subcutaneous tissue disorders	2	(0.8)	2	1.29	0			
Alopecia	1	(0.4)	1	0.64	0			
Urticaria	1	(0.4)	1	0.64	0			
Infections and infestations	1	(0.4)	1	0.64	0			
COVID-19	1	(0.4)	1	0.64	0			
Renal and urinary disorders	1	(0.4)	1	0.64	0			
Nephrotic syndrome	1	(0.4)	1	0.64	0			
Respiratory, thoracic and mediastinal disorders	1	(0.4)	1	0.64	0			
Acute respiratory failure	1	(0.4)	1	0.64	0			
Immune system disorders	0				1	(0.4)	1	0.65
Anaphylactic reaction	0				1	(0.4)	1	0.65
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0				1	(0.4)	1	0.65
Pancreatic carcinoma metastatic	0				1	(0.4)	1	0.65
Nervous system disorders	0				1	(0.4)	1	0.65
Thrombotic stroke	0				1	(0.4)	1	0.65

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYE), PYE: Patient years of exposure (1 PYE = 365.25 days). On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. MedDRA version 24.1. Daily basal insulin: IDeg.

adsl.xpt; variable(s): OTMTDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & (AACN1 == "DRUG WITHDRAWN" | (AACN1 == "DRUG INTERRUPTED" & AOUT == "FATAL")) & (ANL06FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:57 - taesocpt/taewdsocptsumontow2sas.txt

7.14.7 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 4 - on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Events	3	(1.0)	3	1.79	3	(1.0)	6	3.60
Infections and infestations	2	(0.7)	2	1.20	0			
COVID-19 pneumonia	1	(0.3)	1	0.60	0			
Pneumonia	1	(0.3)	1	0.60	0			
Skin and subcutaneous tissue disorders	1	(0.3)	1	0.60	0			
Urticaria	1	(0.3)	1	0.60	0			
Gastrointestinal disorders	0				1	(0.3)	1	0.60
Upper gastrointestinal haemorrhage	0				1	(0.3)	1	0.60
Hepatobiliary disorders	0				1	(0.3)	1	0.60
Liver disorder	0				1	(0.3)	1	0.60
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0				1	(0.3)	1	0.60
Lung adenocarcinoma	0				1	(0.3)	1	0.60
Nervous system disorders	0				1	(0.3)	2	1.20
Cognitive disorder	0				1	(0.3)	1	0.60
Diabetic neuropathy	0				1	(0.3)	1	0.60
Renal and urinary disorders	0				1	(0.3)	1	0.60
Hydrocalyx	0				1	(0.3)	1	0.60

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYE), PYE: Patient years of exposure (1 PYE = 365.25 days). On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. MedDRA version 24.1. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): OTMTDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & (AACN1 == "DRUG WITHDRAWN" | (AACN1 == "DRUG INTERRUPTED" & AOUT == "FATAL")) & (ANL06FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:12:00 - taesocpt/taewdsocptsumontow4sas.txt

7.14.8 Adverse events leading to permanent discontinuation of insulin icodec or daily basal insulin by system organ class and preferred term - ONWARDS 6 (main part) - main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Events	0				1	(0.3)	1	0.69
Metabolism and nutrition disorders	0				1	(0.3)	1	0.69
Insulin resistance	0				1	(0.3)	1	0.69

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYE), PYE: Patient years of exposure (1 PYE = 365.25 days). On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. MedDRA version 24.1. Daily basal insulin: IDeg.

adsl.xpt; variable(s): OTMTDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & (AACN1 == "DRUG WITHDRAWN" | (AACN1 == "DRUG INTERRUPTED" & AOUT == "FATAL")) & (ANL06FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:12:02 - taesocpt/taewdsocptsumontow6sas.txt

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
15. 注目すべき安全性領域（試験別）

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.15.1 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 4
7.15.2 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set 5
7.15.3 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set 6
7.15.4 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 7
7.15.5 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in- trial - summary - safety analysis set.....8
7.15.6 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set.....8
7.15.7 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set.....9
7.15.8 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in- trial - summary - safety analysis set.....9
7.15.9 Localized amyloidosis (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set.....10
7.15.10 Localized amyloidosis (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set.....10
7.15.11 Localized amyloidosis (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set.....10
7.15.12 Localized amyloidosis (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set.....10
7.15.13 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 10
7.15.14 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set 11
7.15.15 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set 11
7.15.16 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 11
7.15.17 Lipodystrophy (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set.....12
7.15.18 Lipodystrophy (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set 12
7.15.19 Lipodystrophy (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set 13
7.15.20 Lipodystrophy (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set.....13

7.15.21 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 14
7.15.22 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in- trial - summary - safety analysis set 14
7.15.23 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in- trial - summary - safety analysis set 14
7.15.24 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 15
7.15.25 Neoplasms (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 15
7.15.26 Neoplasms (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set 16
7.15.27 Neoplasms (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set 17
7.15.28 Neoplasms (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 18
7.15.29 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 19
7.15.30 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set 20
7.15.31 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set 21
7.15.32 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 22
7.15.33 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 23
7.15.34 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set 24
7.15.35 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set 25
7.15.36 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 26
7.15.37 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 27
7.15.38 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set 27
7.15.39 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set 28
7.15.40 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 29
7.15.41 Rare events (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 30
7.15.42 Rare events (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set 31
7.15.43 Rare events (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set 32
7.15.44 Rare events (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 33

7.15.45 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set 34
7.15.46 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in- trial - summary - safety analysis set 35
7.15.47 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in- trial - summary - safety analysis set 36
7.15.48 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set 37

7.15 Safety focus areas by trial

7.15.1 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	4	(0.8)	4	0.82	4	(0.8)	4	0.82
Serious								
Yes	0				0			
No	4	(0.8)	4	0.82	4	(0.8)	4	0.82
Missing	0				0			
Severity								
Severe	0				0			
Moderate	0				2	(0.4)	2	0.41
Mild	4	(0.8)	4	0.82	2	(0.4)	2	0.41
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	4	(0.8)	4	0.82	4	(0.8)	4	0.82
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	4	(0.8)	4	0.82	4	(0.8)	4	0.82
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	3	(0.6)	3	0.61	2	(0.4)	2	0.41
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	1	(0.2)	1	0.20	2	(0.4)	2	0.41
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.2 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Serious								
Yes	0				0			
No	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Missing	0				0			
Severity								
Severe	0				0			
Moderate	1	(0.4)	1	0.64	0			
Mild	0				1	(0.4)	1	0.64
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	1	(0.4)	1	0.64	1	(0.4)	1	0.64
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	1	(0.4)	1	0.64	0			
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				1	(0.4)	1	0.64
Recovered/resolved	0				0			
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & ANELFL == "Y" & ANL01FL == "Y" & CQ14NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:46 - taesum/taemicrovsumintow2sas.txt

7.15.3 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	3	(1.0)	3	1.76	2	(0.7)	2	1.18
Serious								
Yes	1	(0.3)	1	0.59	0			
No	2	(0.7)	2	1.18	2	(0.7)	2	1.18
Missing	0				0			
Severity								
Severe	1	(0.3)	1	0.59	0			
Moderate	1	(0.3)	1	0.59	0			
Mild	1	(0.3)	1	0.59	2	(0.7)	2	1.18
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	3	(1.0)	3	1.76	2	(0.7)	2	1.18
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	3	(1.0)	3	1.76	2	(0.7)	2	1.18
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	1	(0.3)	1	0.59	2	(0.7)	2	1.18
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	2	(0.7)	2	1.18	0			
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" &
ANELFL == "Y" & ANL01FL == "Y" & CQ14NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:48 - taesum/taemicrovsumintow4sas.txt

7.15.4 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Serious								
Yes	0				0			
No	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Missing	0				0			
Severity								
Severe	0				0			
Moderate	0				0			
Mild	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	2	(0.7)	2	1.40	2	(0.7)	2	1.38
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	1	(0.3)	1	0.70	0			
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & ANELFL == "Y" & ANL01FL == "Y" & CQ14NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:49 - taesum/taemicrovsumintow6sas.txt

7.15.5 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in- trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	4	(0.8)	4	0.82	4	(0.8)	4	0.82
Renal and urinary disorders	3	(0.6)	3	0.61	0			
Diabetic nephropathy	2	(0.4)	2	0.41	0			
Microalbuminuria	1	(0.2)	1	0.20	0			
Nervous system disorders	1	(0.2)	1	0.20	3	(0.6)	3	0.62
Diabetic neuropathy	1	(0.2)	1	0.20	3	(0.6)	3	0.62
Skin and subcutaneous tissue disorders	0				1	(0.2)	1	0.21
Diabetic foot	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & CQ14NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:47 - taesocpt/taesocptmicrovsumintow1sas.txt

7.15.6 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Renal and urinary disorders	1	(0.4)	1	0.64	0			
Diabetic nephropathy	1	(0.4)	1	0.64	0			
Nervous system disorders	0				1	(0.4)	1	0.64
Diabetic neuropathy	0				1	(0.4)	1	0.64

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ14NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:50 - taesocpt/taesocptmicrovsumintow2sas.txt

7.15.7 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	3	(1.0)	3	1.76	2	(0.7)	2	1.18
Nervous system disorders	2	(0.7)	2	1.18	2	(0.7)	2	1.18
Diabetic neuropathy	2	(0.7)	2	1.18	2	(0.7)	2	1.18
Infections and infestations	1	(0.3)	1	0.59	0			
Diabetic foot infection	1	(0.3)	1	0.59	0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & CQ14NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:52 - taesocpt/taesocptmicrovsumintow4sas.txt

7.15.8 Other microvascular diabetic complications (peripheral vascular disease and renal impairment) (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in- trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Nervous system disorders	1	(0.3)	1	0.70	0			
Diabetic neuropathy	1	(0.3)	1	0.70	0			
Renal and urinary disorders	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Microalbuminuria	1	(0.3)	1	0.70	0			
Diabetic nephropathy	0				2	(0.7)	2	1.38

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & CQ14NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:55 - taesocpt/taesocptmicrovsumintow6sas.txt

7.15.9 Localized amyloidosis (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

```
There is no data for this output
```

```
                    adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" &
                                                      ANELFL == "Y" & ANL01FL == "Y" & CQ13NAM != ""
                                                          nn1436/nn1436-japan/submission_20221031_er
                                                 09NOV2022:10:10:58 - taesum/taeamylsumintow1sas.txt
```

7.15.10 Localized amyloidosis (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

```
There is no data for this output
```

```
                    adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" &
                                                      ANELFL == "Y" & ANL01FL == "Y" & CQ13NAM != ""
                                                          nn1436/nn1436-japan/submission_20221031_er
                                                 09NOV2022:10:11:00 - taesum/taeamylsumintow2sas.txt
```

7.15.11 Localized amyloidosis (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

```
There is no data for this output
```

```
                    adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" &
                                                      ANELFL == "Y" & ANL01FL == "Y" & CQ13NAM != ""
                                                          nn1436/nn1436-japan/submission_20221031_er
                                                 09NOV2022:10:11:02 - taesum/taeamylsumintow4sas.txt
```

7.15.12 Localized amyloidosis (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

```
There is no data for this output
```

```
                    adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" &
                                                      ANELFL == "Y" & ANL01FL == "Y" & CQ13NAM != ""
                                                          nn1436/nn1436-japan/submission_20221031_er
                                                 09NOV2022:10:11:03 - taesum/taeamylsumintow6sas.txt
```

7.15.13 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

```
There is no data for this output
```

```
                     adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
 adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & CQ13NAM !=
                                                        "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
                                                          nn1436/nn1436-japan/submission_20221031_er
                                                 09NOV2022:10:10:58 - taesocpt/taesocptamylsumintow1sas.txt
```

7.15.14 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

```
There is no data for this output
```

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ13NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:01 - taesocpt/taesocptamylsumintow2sas.txt

7.15.15 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

```
There is no data for this output
```

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & CQ13NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:03 - taesocpt/taesocptamylsumintow4sas.txt

7.15.16 Localized amyloidosis (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

```
There is no data for this output
```

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & CQ13NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:05 - taesocpt/taesocptamylsumintow6sas.txt

7.15.17 Lipodystrophy (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Serious								
Yes	0				0			
No	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Missing	0				0			
Severity								
Severe	0				0			
Moderate	0				0			
Mild	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Missing	0				0			
Related to basal insulin								
Probable	1	(0.2)	1	0.20	0			
Possible	0				1	(0.2)	1	0.21
Unlikely	0				0			
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	1	(0.2)	1	0.20	1	(0.2)	1	0.21
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	0				1	(0.2)	1	0.21
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.2)	1	0.20	0			
Recovered/resolved	0				0			
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & ANELFL == "Y" & ANL01FL == "Y" & CQ12NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:51 - taesum/taeliposumintow1sas.txt

7.15.18 Lipodystrophy (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

There is no data for this output

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & ANELFL == "Y" & ANL01FL == "Y" & CQ12NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:52 - taesum/taeliposumintow2sas.txt

7.15.19 Lipodystrophy (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	0				1	(0.3)	1	0.59
Serious								
Yes	0				0			
No	0				1	(0.3)	1	0.59
Missing	0				0			
Severity								
Severe	0				0			
Moderate	0				0			
Mild	0				1	(0.3)	1	0.59
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	0				1	(0.3)	1	0.59
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	0				1	(0.3)	1	0.59
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	0				0			
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	0				1	(0.3)	1	0.59
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & ANELFL == "Y" & ANL01FL == "Y" & CQ12NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:54 - taesum/taeliposumintow4sas.txt

7.15.20 Lipodystrophy (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

There is no data for this output

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & ANELFL == "Y" & ANL01FL == "Y" & CQ12NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:10:56 - taesum/taeliposumintow6sas.txt

7.15.21 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Skin and subcutaneous tissue disorders	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Lipodystrophy acquired	1	(0.2)	1	0.20	0			
Lipohypertrophy	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & CQ12NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:08 - taesocpt/taesocptliposumintow1sas.txt

7.15.22 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in- trial - summary - safety analysis set

There is no data for this output

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ12NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:10 - taesocpt/taesocptliposumintow2sas.txt

7.15.23 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in- trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	0				1	(0.3)	1	0.59
Skin and subcutaneous tissue disorders	0				1	(0.3)	1	0.59
Lipohypertrophy	0				1	(0.3)	1	0.59

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & CQ12NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:12 - taesocpt/taesocptliposumintow4sas.txt

7.15.24 Lipodystrophy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

There is no data for this output

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & CQ12NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:15 - taesocpt/taesocptliposumintow6sas.txt

7.15.25 Neoplasms (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	20	(4.1)	24	4.92	12	(2.4)	20	4.11
Serious								
Yes	3	(0.6)	4	0.82	4	(0.8)	6	1.23
No	17	(3.5)	20	4.10	10	(2.0)	14	2.88
Missing	0				0			
Severity								
Severe	1	(0.2)	2	0.41	2	(0.4)	3	0.62
Moderate	4	(0.8)	4	0.82	4	(0.8)	4	0.82
Mild	15	(3.0)	18	3.69	7	(1.4)	13	2.67
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	20	(4.1)	24	4.92	12	(2.4)	20	4.11
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	20	(4.1)	24	4.92	12	(2.4)	20	4.11
NA	0				0			
Missing	0				0			
Outcome								
Fatal	2	(0.4)	3	0.61	0			
Not recovered/not resolved	10	(2.0)	12	2.46	8	(1.6)	12	2.46
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.2)	1	0.20	0			
Recovered/resolved	8	(1.6)	8	1.64	7	(1.4)	8	1.64
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & ANELFL == "Y" & ANL01FL == "Y" & CQ11NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:05 - taesum/taeneoplsumintow1sas.txt

7.15.26 Neoplasms (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	7	(2.7)	7	4.47	8	(3.0)	8	5.13
Serious								
Yes	2	(0.8)	2	1.28	3	(1.1)	3	1.92
No	5	(1.9)	5	3.19	5	(1.9)	5	3.21
Missing	0				0			
Severity								
Severe	1	(0.4)	1	0.64	2	(0.8)	2	1.28
Moderate	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Mild	5	(1.9)	5	3.19	5	(1.9)	5	3.21
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	7	(2.7)	7	4.47	8	(3.0)	8	5.13
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	7	(2.7)	7	4.47	8	(3.0)	8	5.13
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				1	(0.4)	1	0.64
Not recovered/not resolved	5	(1.9)	5	3.19	3	(1.1)	3	1.92
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	2	(0.8)	2	1.28	4	(1.5)	4	2.57
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

7.15.27 Neoplasms (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	6	(2.1)	6	3.53	9	(3.1)	11	6.47
Serious								
Yes	2	(0.7)	2	1.18	2	(0.7)	3	1.76
No	4	(1.4)	4	2.35	8	(2.7)	8	4.71
Missing	0				0			
Severity								
Severe	0				1	(0.3)	1	0.59
Moderate	4	(1.4)	4	2.35	1	(0.3)	2	1.18
Mild	2	(0.7)	2	1.18	8	(2.7)	8	4.71
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	6	(2.1)	6	3.53	9	(3.1)	11	6.47
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	6	(2.1)	6	3.53	9	(3.1)	11	6.47
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	3	(1.0)	3	1.76	8	(2.7)	8	4.71
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.3)	1	0.59	2	(0.7)	2	1.18
Recovered/resolved	2	(0.7)	2	1.18	1	(0.3)	1	0.59
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.28 Neoplasms (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	8	(2.8)	8	5.58	9	(3.1)	11	7.60
Serious								
Yes	0				0			
No	8	(2.8)	8	5.58	9	(3.1)	11	7.60
Missing	0				0			
Severity								
Severe	0				0			
Moderate	0				0			
Mild	8	(2.8)	8	5.58	9	(3.1)	11	7.60
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	8	(2.8)	8	5.58	9	(3.1)	11	7.60
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	8	(2.8)	8	5.58	9	(3.1)	11	7.60
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	5	(1.7)	5	3.49	7	(2.4)	9	6.22
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Recovered/resolved	2	(0.7)	2	1.40	1	(0.3)	1	0.69
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

7.15.29 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	20	(4.1)	24	4.92	12	(2.4)	20	4.11
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	11	(2.2)	13	2.66	5	(1.0)	9	1.85
Seborrhoeic keratosis	2	(0.4)	3	0.61	0			
Acrochordon	1	(0.2)	1	0.20	0			
Basal cell carcinoma	1	(0.2)	1	0.20	2	(0.4)	2	0.41
Glioblastoma multiforme	1	(0.2)	1	0.20	0			
Haemangioma of liver	1	(0.2)	1	0.20	0			
Metastases to liver	1	(0.2)	1	0.20	0			
Neoplasm skin	1	(0.2)	1	0.20	0			
Oral fibroma	1	(0.2)	1	0.20	0			
Pancreatic neoplasm	1	(0.2)	1	0.20	0			
Prostate cancer	1	(0.2)	1	0.20	0			
Salivary gland neoplasm	1	(0.2)	1	0.20	0			
Colon cancer	0				1	(0.2)	1	0.21
Dysplastic naevus	0				1	(0.2)	1	0.21
Hepatocellular carcinoma	0				1	(0.2)	1	0.21
Malignant melanoma in situ	0				1	(0.2)	1	0.21
Ovarian cancer metastatic	0				1	(0.2)	1	0.21
Renal cell carcinoma	0				1	(0.2)	1	0.21
Uterine leiomyoma	0				1	(0.2)	1	0.21
Gastrointestinal disorders	3	(0.6)	3	0.61	4	(0.8)	6	1.23
Gastric polyps	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Large intestine polyp	1	(0.2)	1	0.20	2	(0.4)	3	0.62
Rectal polyp	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Crohn's disease	0				1	(0.2)	1	0.21
Musculoskeletal and connective tissue disorders	3	(0.6)	3	0.61	0			
Synovial cyst	2	(0.4)	2	0.41	0			
Bone cyst	1	(0.2)	1	0.20	0			
Renal and urinary disorders	2	(0.4)	2	0.41	0			
Renal cyst	2	(0.4)	2	0.41	0			
Reproductive system and breast disorders	2	(0.4)	2	0.41	0			
Ovarian cyst	1	(0.2)	1	0.20	0			
Uterine polyp	1	(0.2)	1	0.20	0			
Respiratory, thoracic and mediastinal disorders	1	(0.2)	1	0.20	0			
Laryngeal cyst	1	(0.2)	1	0.20	0			
Skin and subcutaneous tissue disorders	0				3	(0.6)	3	0.62
Dermal cyst	0				2	(0.4)	2	0.41
Actinic keratosis	0				1	(0.2)	1	0.21
Hepatobiliary disorders	0				1	(0.2)	1	0.21
Hepatic cyst	0				1	(0.2)	1	0.21
Surgical and medical procedures	0				1	(0.2)	1	0.21
Large intestinal polypectomy	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.30 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	7	(2.7)	7	4.47	8	(3.0)	8	5.13
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	3	(1.1)	3	1.92	4	(1.5)	4	2.57
Chronic myeloid leukaemia	1	(0.4)	1	0.64	0			
Colon adenoma	1	(0.4)	1	0.64	0			
Gastric cancer	1	(0.4)	1	0.64	0			
Breast cancer	0				1	(0.4)	1	0.64
Colon cancer stage II	0				1	(0.4)	1	0.64
Lymphangioma	0				1	(0.4)	1	0.64
Pancreatic carcinoma metastatic	0				1	(0.4)	1	0.64
Gastrointestinal disorders	1	(0.4)	1	0.64	3	(1.1)	3	1.92
Large intestine polyp	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Gastric dysplasia	0				1	(0.4)	1	0.64
Gastric polyps	0				1	(0.4)	1	0.64
Hepatobiliary disorders	1	(0.4)	1	0.64	0			
Gallbladder polyp	1	(0.4)	1	0.64	0			
Renal and urinary disorders	1	(0.4)	1	0.64	0			
Renal cyst	1	(0.4)	1	0.64	0			
Reproductive system and breast disorders	1	(0.4)	1	0.64	0			
Cervical polyp	1	(0.4)	1	0.64	0			
Skin and subcutaneous tissue disorders	0				1	(0.4)	1	0.64
Dermal cyst	0				1	(0.4)	1	0.64

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ11NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:20 - taesocpt/taesocptneoplsumintow2sas.txt

7.15.31 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	6	(2.1)	6	3.53	9	(3.1)	11	6.47
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	4	(1.4)	4	2.35	3	(1.0)	5	2.94
Eye naevus	1	(0.3)	1	0.59	0			
Osteoma	1	(0.3)	1	0.59	0			
Pancreatic neoplasm	1	(0.3)	1	0.59	0			
Small cell lung cancer	1	(0.3)	1	0.59	0			
Adrenal adenoma	0				1	(0.3)	1	0.59
Lung adenocarcinoma	0				1	(0.3)	1	0.59
Small intestine neuroendocrine tumour	0				1	(0.3)	1	0.59
Uterine cancer	0				1	(0.3)	1	0.59
Uterine leiomyoma	0				1	(0.3)	1	0.59
Infections and infestations	1	(0.3)	1	0.59	0			
Infected dermal cyst	1	(0.3)	1	0.59	0			
Renal and urinary disorders	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Renal cyst	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Respiratory, thoracic and mediastinal disorders	0				2	(0.7)	2	1.18
Paranasal cyst	0				2	(0.7)	2	1.18
General disorders and administration site conditions	0				1	(0.3)	1	0.59
Cyst	0				1	(0.3)	1	0.59
Hepatobiliary disorders	0				1	(0.3)	1	0.59
Gallbladder polyp	0				1	(0.3)	1	0.59
Musculoskeletal and connective tissue disorders	0				1	(0.3)	1	0.59
Bone cyst	0				1	(0.3)	1	0.59

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.32 Neoplasms (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	8	(2.8)	8	5.58	9	(3.1)	11	7.60
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	4	(1.4)	4	2.79	2	(0.7)	3	2.07
Benign neoplasm of thyroid gland	1	(0.3)	1	0.70	0			
Eye naevus	1	(0.3)	1	0.70	0			
Haemangioma of liver	1	(0.3)	1	0.70	0			
Melanocytic naevus	1	(0.3)	1	0.70	0			
Uterine leiomyoma	0				2	(0.7)	2	1.38
Benign renal neoplasm	0				1	(0.3)	1	0.69
Hepatobiliary disorders	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Gallbladder polyp	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Musculoskeletal and connective tissue disorders	1	(0.3)	1	0.70	0			
Synovial cyst	1	(0.3)	1	0.70	0			
Skin and subcutaneous tissue disorders	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Dermal cyst	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Surgical and medical procedures	1	(0.3)	1	0.70	0			
Skin neoplasm excision	1	(0.3)	1	0.70	0			
Gastrointestinal disorders	0				2	(0.7)	2	1.38
Gastric polyps	0				2	(0.7)	2	1.38
Infections and infestations	0				1	(0.3)	1	0.69
Infected cyst	0				1	(0.3)	1	0.69
Renal and urinary disorders	0				1	(0.3)	1	0.69
Renal cyst	0				1	(0.3)	1	0.69
Reproductive system and breast disorders	0				1	(0.3)	1	0.69
Fibrocystic breast disease	0				1	(0.3)	1	0.69

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & CQ11NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:25 - taesocpt/taesocptneoplsumintow6sas.txt

7.15.33 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	6	(1.2)	8	1.64	10	(2.0)	11	2.26
Serious								
Yes	0				1	(0.2)	1	0.21
No	6	(1.2)	8	1.64	9	(1.8)	10	2.05
Missing	0				0			
Severity								
Severe	0				0			
Moderate	1	(0.2)	3	0.61	4	(0.8)	5	1.03
Mild	5	(1.0)	5	1.02	6	(1.2)	6	1.23
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	1	(0.2)	1	0.20	3	(0.6)	3	0.62
Unlikely	6	(1.2)	7	1.43	7	(1.4)	8	1.64
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	6	(1.2)	8	1.64	10	(2.0)	11	2.26
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	5	(1.0)	6	1.23	6	(1.2)	7	1.44
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.2)	1	0.20	0			
Recovered/resolved	1	(0.2)	1	0.20	4	(0.8)	4	0.82
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.34 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	17	(6.5)	21	13.41	18	(6.8)	21	13.47
Serious								
Yes	1	(0.4)	1	0.64	0			
No	16	(6.1)	20	12.77	18	(6.8)	21	13.47
Missing	0				0			
Severity								
Severe	0				1	(0.4)	1	0.64
Moderate	6	(2.3)	10	6.39	2	(0.8)	4	2.57
Mild	11	(4.2)	11	7.02	15	(5.7)	16	10.26
Missing	0				0			
Related to basal insulin								
Probable	1	(0.4)	1	0.64	0			
Possible	0				1	(0.4)	1	0.64
Unlikely	16	(6.1)	20	12.77	17	(6.5)	20	12.83
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	16	(6.1)	20	12.77	17	(6.5)	20	12.83
NA	1	(0.4)	1	0.64	1	(0.4)	1	0.64
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	14	(5.3)	18	11.49	16	(6.1)	19	12.19
Recovered/resolved with sequelae	0				0			
Recovering/resolving	3	(1.1)	3	1.92	1	(0.4)	1	0.64
Recovered/resolved	0				1	(0.4)	1	0.64
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

7.15.35 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	23	(7.9)	30	17.65	26	(8.9)	40	23.53
Serious								
Yes	0				2	(0.7)	3	1.76
No	23	(7.9)	30	17.65	25	(8.6)	37	21.77
Missing	0				0			
Severity								
Severe	0				0			
Moderate	3	(1.0)	3	1.76	4	(1.4)	8	4.71
Mild	20	(6.9)	27	15.88	22	(7.6)	32	18.83
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	6	(2.1)	7	4.12	3	(1.0)	12	7.06
Unlikely	18	(6.2)	23	13.53	23	(7.9)	28	16.47
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	23	(7.9)	30	17.65	26	(8.9)	40	23.53
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	19	(6.5)	24	14.12	19	(6.5)	24	14.12
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	4	(1.4)	6	3.53	7	(2.4)	16	9.41
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.36 Diabetic retinopathy or maculopathy (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	22	(7.6)	26	18.15	21	(7.2)	25	17.28
Serious								
Yes	0				0			
No	22	(7.6)	26	18.15	21	(7.2)	25	17.28
Missing	0				0			
Severity								
Severe	0				0			
Moderate	3	(1.0)	4	2.79	2	(0.7)	2	1.38
Mild	20	(6.9)	22	15.36	19	(6.5)	23	15.90
Missing	0				0			
Related to basal insulin								
Probable	1	(0.3)	1	0.70	0			
Possible	5	(1.7)	5	3.49	2	(0.7)	2	1.38
Unlikely	16	(5.5)	20	13.96	19	(6.5)	23	15.90
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	22	(7.6)	26	18.15	21	(7.2)	25	17.28
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	21	(7.2)	25	17.45	21	(7.2)	24	16.59
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

7.15.37 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	6	(1.2)	8	1.64	10	(2.0)	11	2.26
Eye disorders	6	(1.2)	8	1.64	10	(2.0)	11	2.26
Diabetic retinopathy	3	(0.6)	3	0.61	4	(0.8)	4	0.82
Macular oedema	1	(0.2)	1	0.20	0			
Post thrombotic retinopathy	1	(0.2)	1	0.20	0			
Retinal aneurysm	1	(0.2)	1	0.20	0			
Retinal tear	1	(0.2)	1	0.20	0			
Vitreous detachment	1	(0.2)	1	0.20	0			
Diabetic retinal oedema	0				1	(0.2)	1	0.21
Retinal artery occlusion	0				1	(0.2)	1	0.21
Retinal detachment	0				1	(0.2)	1	0.21
Retinal vein occlusion	0				1	(0.2)	1	0.21
Scintillating scotoma	0				1	(0.2)	1	0.21
Visual impairment	0				1	(0.2)	1	0.21
Vitreous haemorrhage	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & CQ08NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:27 - taesocpt/taesocptdiaretsumintow1sas.txt

7.15.38 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	17	(6.5)	21	13.41	18	(6.8)	21	13.47
Eye disorders	17	(6.5)	21	13.41	18	(6.8)	21	13.47
Diabetic retinopathy	10	(3.8)	11	7.02	16	(6.1)	17	10.90
Diabetic retinal oedema	2	(0.8)	2	1.28	2	(0.8)	2	1.28
Macular oedema	2	(0.8)	2	1.28	0			
Dry age-related macular degeneration	1	(0.4)	1	0.64	0			
Epiretinal membrane	1	(0.4)	1	0.64	0			
Retinal exudates	1	(0.4)	1	0.64	0			
Retinal haemorrhage	1	(0.4)	1	0.64	0			
Retinal vein occlusion	1	(0.4)	1	0.64	0			
Vitreous haemorrhage	1	(0.4)	1	0.64	0			
Non-proliferative retinopathy	0				1	(0.4)	1	0.64
Visual acuity reduced	0				1	(0.4)	1	0.64

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ08NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:29 - taesocpt/taesocptdiaretsumintow2sas.txt

7.15.39 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	23	(7.9)	30	17.65	26	(8.9)	40	23.53
Eye disorders	23	(7.9)	29	17.06	26	(8.9)	40	23.53
Diabetic retinopathy	12	(4.1)	14	8.23	15	(5.2)	15	8.82
Macular oedema	3	(1.0)	3	1.76	1	(0.3)	1	0.59
Diabetic retinal oedema	2	(0.7)	2	1.18	3	(1.0)	4	2.35
Retinal haemorrhage	2	(0.7)	2	1.18	0			
Retinopathy hypertensive	2	(0.7)	2	1.18	4	(1.4)	4	2.35
Age-related macular degeneration	1	(0.3)	1	0.59	0			
Retinal deposits	1	(0.3)	1	0.59	0			
Retinal drusen	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Retinal scar	1	(0.3)	1	0.59	0			
Vitreous detachment	1	(0.3)	1	0.59	0			
Vitreous haemorrhage	1	(0.3)	1	0.59	1	(0.3)	1	0.59
Retinal exudates	0				2	(0.7)	2	1.18
Macular degeneration	0				1	(0.3)	1	0.59
Retinal detachment	0				1	(0.3)	1	0.59
Retinal vascular disorder	0				1	(0.3)	1	0.59
Visual impairment	0				1	(0.3)	9	5.29
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	(0.3)	1	0.59	0			
Eye naevus	1	(0.3)	1	0.59	0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.40 Diabetic retinopathy or maculopathy (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	22	(7.6)	26	18.15	21	(7.2)	25	17.28
Eye disorders	21	(7.2)	25	17.45	21	(7.2)	25	17.28
Diabetic retinopathy	12	(4.1)	12	8.38	14	(4.8)	14	9.68
Macular oedema	3	(1.0)	4	2.79	1	(0.3)	1	0.69
Diabetic retinal oedema	2	(0.7)	2	1.40	1	(0.3)	1	0.69
Non-proliferative retinopathy	2	(0.7)	2	1.40	2	(0.7)	2	1.38
Retinopathy hypertensive	2	(0.7)	2	1.40	0			
Arteriosclerotic retinopathy	1	(0.3)	1	0.70	0			
Epiretinal membrane	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Retinal vascular disorder	1	(0.3)	1	0.70	0			
Vitreous detachment	0				2	(0.7)	2	1.38
Vitreous floaters	0				2	(0.7)	2	1.38
Photopsia	0				1	(0.3)	1	0.69
Retinopathy	0				1	(0.3)	1	0.69
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	(0.3)	1	0.70	0			
Eye naevus	1	(0.3)	1	0.70	0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 6" & CQ08NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:35 - taesocpt/taesocptdiaretsumintow6sas.txt

7.15.41 Rare events (predefined MedDRA search) - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	38	(7.7)	45	9.22	28	(5.7)	36	7.39
Serious								
Yes	7	(1.4)	9	1.84	6	(1.2)	8	1.64
No	34	(6.9)	36	7.38	23	(4.7)	28	5.75
Missing	0				0			
Severity								
Severe	0				4	(0.8)	6	1.23
Moderate	9	(1.8)	10	2.05	7	(1.4)	9	1.85
Mild	32	(6.5)	35	7.17	18	(3.7)	21	4.31
Missing	0				0			
Related to basal insulin								
Probable	0				2	(0.4)	2	0.41
Possible	2	(0.4)	2	0.41	1	(0.2)	1	0.21
Unlikely	36	(7.3)	43	8.81	26	(5.3)	33	6.78
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	38	(7.7)	45	9.22	28	(5.7)	36	7.39
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	18	(3.7)	21	4.30	13	(2.6)	15	3.08
Recovered/resolved with sequelae	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Recovering/resolving	4	(0.8)	4	0.82	0			
Recovered/resolved	18	(3.7)	19	3.89	16	(3.3)	20	4.11
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.42 Rare events (predefined MedDRA search) - ONWARDS 2 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	6	(2.3)	7	4.47	3	(1.1)	3	1.92
Serious								
Yes	2	(0.8)	2	1.28	1	(0.4)	1	0.64
No	4	(1.5)	5	3.19	2	(0.8)	2	1.28
Missing	0				0			
Severity								
Severe	1	(0.4)	1	0.64	0			
Moderate	2	(0.8)	2	1.28	3	(1.1)	3	1.92
Mild	3	(1.1)	4	2.55	0			
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				0			
Unlikely	6	(2.3)	7	4.47	3	(1.1)	3	1.92
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	6	(2.3)	7	4.47	3	(1.1)	3	1.92
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	3	(1.1)	4	2.55	3	(1.1)	3	1.92
Recovered/resolved with sequelae	0				0			
Recovering/resolving	1	(0.4)	1	0.64	0			
Recovered/resolved	2	(0.8)	2	1.28	0			
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & ANELFL == "Y" & ANL01FL == "Y" & CQ05NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:20 - taesum/taeraresumintow2sas.txt

7.15.43 Rare events (predefined MedDRA search) - ONWARDS 4 - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	2	(0.7)	5	2.94	11	(3.8)	11	6.47
Serious								
Yes	1	(0.3)	2	1.18	0			
No	2	(0.7)	3	1.76	11	(3.8)	11	6.47
Missing	0				0			
Severity								
Severe	1	(0.3)	2	1.18	0			
Moderate	0				2	(0.7)	2	1.18
Mild	2	(0.7)	3	1.76	9	(3.1)	9	5.29
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	0				1	(0.3)	1	0.59
Unlikely	2	(0.7)	5	2.94	10	(3.4)	10	5.88
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	2	(0.7)	5	2.94	11	(3.8)	11	6.47
NA	0				0			
Missing	0				0			
Outcome								
Fatal	1	(0.3)	2	1.18	0			
Not recovered/not resolved	2	(0.7)	3	1.76	8	(2.7)	8	4.71
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	0				3	(1.0)	3	1.76
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt ; variable(s): INTRDURY ; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT; criteria: SAFFL == "Y" & STDNM == "ONWARDS 4" & ANELFL == "Y" & ANL01FL == "Y" & CQ05NAM != ""
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:22 - taesum/taeraresumintow4sas.txt

7.15.44 Rare events (predefined MedDRA search) - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	14	(4.8)	14	9.77	7	(2.4)	7	4.84
Serious								
Yes	0				0			
No	14	(4.8)	14	9.77	7	(2.4)	7	4.84
Missing	0				0			
Severity								
Severe	1	(0.3)	1	0.70	0			
Moderate	3	(1.0)	3	2.09	2	(0.7)	2	1.38
Mild	10	(3.4)	10	6.98	5	(1.7)	5	3.46
Missing	0				0			
Related to basal insulin								
Probable	0				0			
Possible	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Unlikely	13	(4.5)	13	9.08	6	(2.1)	6	4.15
Missing	0				0			
Related to technical complaint for basal insulin								
Yes	0				0			
No	14	(4.8)	14	9.77	7	(2.4)	7	4.84
NA	0				0			
Missing	0				0			
Outcome								
Fatal	0				0			
Not recovered/not resolved	9	(3.1)	9	6.28	3	(1.0)	3	2.07
Recovered/resolved with sequelae	0				0			
Recovering/resolving	0				0			
Recovered/resolved	5	(1.7)	5	3.49	4	(1.4)	4	2.76
Unknown	0				0			
Missing	0				0			

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 22.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

7.15.45 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	492				492			
PYO (years)	488.06				486.95			
Events	38	(7.7)	45	9.22	28	(5.7)	36	7.39
Cardiac disorders	18	(3.7)	22	4.51	17	(3.5)	20	4.11
Atrial fibrillation	8	(1.6)	9	1.84	4	(0.8)	4	0.82
Ventricular extrasystoles	5	(1.0)	5	1.02	1	(0.2)	1	0.21
Palpitations	3	(0.6)	3	0.61	3	(0.6)	3	0.62
Atrial flutter	1	(0.2)	1	0.20	0			
Bradycardia	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Bundle branch block right	1	(0.2)	1	0.20	2	(0.4)	3	0.62
Sinus tachycardia	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Supraventricular extrasystoles	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Arrhythmia	0				2	(0.4)	2	0.41
Atrioventricular block complete	0				1	(0.2)	1	0.21
Sinus arrhythmia	0				1	(0.2)	1	0.21
Sinus bradycardia	0				1	(0.2)	1	0.21
Tachycardia	0				1	(0.2)	1	0.21
Hepatobiliary disorders	7	(1.4)	8	1.64	5	(1.0)	5	1.03
Hepatic steatosis	6	(1.2)	6	1.23	2	(0.4)	2	0.41
Liver disorder	1	(0.2)	1	0.20	0			
Non-alcoholic steatohepatitis	1	(0.2)	1	0.20	0			
Hepatic cirrhosis	0				1	(0.2)	1	0.21
Nonalcoholic fatty liver disease	0				1	(0.2)	1	0.21
Steatohepatitis	0				1	(0.2)	1	0.21
Nervous system disorders	5	(1.0)	5	1.02	1	(0.2)	1	0.21
Syncope	5	(1.0)	5	1.02	1	(0.2)	1	0.21
Respiratory, thoracic and mediastinal disorders	3	(0.6)	4	0.82	0			
Interstitial lung disease	2	(0.4)	2	0.41	0			
Pulmonary fibrosis	1	(0.2)	2	0.41	0			
Congenital, familial and genetic disorders	2	(0.4)	2	0.41	1	(0.2)	1	0.21
Hydrocele	1	(0.2)	1	0.20	0			
Type V hyperlipidaemia	1	(0.2)	1	0.20	0			
Congenital syphilitic osteochondritis	0				1	(0.2)	1	0.21
Renal and urinary disorders	2	(0.4)	2	0.41	3	(0.6)	4	0.82
Renal impairment	2	(0.4)	2	0.41	2	(0.4)	2	0.41
Acute kidney injury	0				1	(0.2)	1	0.21
Urinary tract obstruction	0				1	(0.2)	1	0.21
Blood and lymphatic system disorders	1	(0.2)	1	0.20	0			
Thrombocytopenia	1	(0.2)	1	0.20	0			
Gastrointestinal disorders	1	(0.2)	1	0.20	3	(0.6)	3	0.62
Pancreatitis	1	(0.2)	1	0.20	1	(0.2)	1	0.21
Pancreatitis acute	0				1	(0.2)	1	0.21
Pancreatitis chronic	0				1	(0.2)	1	0.21
Infections and infestations	0				1	(0.2)	1	0.21
Clostridium difficile infection	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 1 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Investigations	0				1	(0.2)	1	0.21
Electrocardiogram repolarisation abnormality	0				1	(0.2)	1	0.21

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 1" & CQ05NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:37 - taesocpt/taesocptraresumintow1sas.txt

7.15.46 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 2 - in- trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	262				263			
PYO (years)	156.59				155.90			
Events	6	(2.3)	7	4.47	3	(1.1)	3	1.92
Renal and urinary disorders	3	(1.1)	3	1.92	0			
Hydronephrosis	1	(0.4)	1	0.64	0			
Nephrotic syndrome	1	(0.4)	1	0.64	0			
Renal impairment	1	(0.4)	1	0.64	0			
Cardiac disorders	2	(0.8)	3	1.92	1	(0.4)	1	0.64
Atrial fibrillation	1	(0.4)	1	0.64	0			
Cardiac flutter	1	(0.4)	1	0.64	0			
Supraventricular tachycardia	1	(0.4)	1	0.64	0			
Bradycardia	0				1	(0.4)	1	0.64
Nervous system disorders	1	(0.4)	1	0.64	0			
Syncope	1	(0.4)	1	0.64	0			
Gastrointestinal disorders	0				1	(0.4)	1	0.64
Pancreatic pseudocyst	0				1	(0.4)	1	0.64
Hepatobiliary disorders	0				1	(0.4)	1	0.64
Hepatic cirrhosis	0				1	(0.4)	1	0.64

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.

adsl.xpt; variable(s): INTRDURY; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2"
adae.xpt; variable(s): AEBODSYS AEDECOD; criteria: SAFFL == "Y" & STDNM == "ONWARDS 2" & CQ05NAM != "" & (ANL01FL) == "Y" & (ANELFL) == "Y"
nn1436/nn1436-japan/submission_20221031_er
09NOV2022:10:11:39 - taesocpt/taesocptraresumintow2sas.txt

7.15.47 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 4 - in- trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	291				291			
PYO (years)	170.01				169.98			
Events	2	(0.7)	5	2.94	11	(3.8)	11	6.47
Congenital, familial and genetic disorders	1	(0.3)	1	0.59	0			
Corneal dystrophy	1	(0.3)	1	0.59	0			
Gastrointestinal disorders	1	(0.3)	1	0.59	0			
Pancreatitis chronic	1	(0.3)	1	0.59	0			
General disorders and administration site conditions	1	(0.3)	1	0.59	0			
Multiple organ dysfunction syndrome	1	(0.3)	1	0.59	0			
Renal and urinary disorders	1	(0.3)	1	0.59	0			
Acute kidney injury	1	(0.3)	1	0.59	0			
Respiratory, thoracic and mediastinal disorders	1	(0.3)	1	0.59	0			
Pulmonary fibrosis	1	(0.3)	1	0.59	0			
Cardiac disorders	0				7	(2.4)	7	4.12
Bundle branch block right	0				2	(0.7)	2	1.18
Atrial fibrillation	0				1	(0.3)	1	0.59
Bundle branch block left	0				1	(0.3)	1	0.59
Palpitations	0				1	(0.3)	1	0.59
Sinus bradycardia	0				1	(0.3)	1	0.59
Tachycardia	0				1	(0.3)	1	0.59
Hepatobiliary disorders	0				2	(0.7)	2	1.18
Hepatic steatosis	0				1	(0.3)	1	0.59
Liver disorder	0				1	(0.3)	1	0.59
Investigations	0				2	(0.7)	2	1.18
Electrocardiogram abnormal	0				1	(0.3)	1	0.59
Platelet count decreased	0				1	(0.3)	1	0.59

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IGlar U100.

7.15.48 Rare events (predefined MedDRA search) by system organ class and preferred term - ONWARDS 6 (main part) - in-trial - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Number of subjects	290				292			
PYO (years)	143.24				144.68			
Events	14	(4.8)	14	9.77	7	(2.4)	7	4.84
Cardiac disorders	6	(2.1)	6	4.19	3	(1.0)	3	2.07
Ventricular extrasystoles	3	(1.0)	3	2.09	0			
Atrial fibrillation	1	(0.3)	1	0.70	0			
Bundle branch block right	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Palpitations	1	(0.3)	1	0.70	2	(0.7)	2	1.38
Hepatobiliary disorders	4	(1.4)	4	2.79	1	(0.3)	1	0.69
Hepatic steatosis	3	(1.0)	3	2.09	1	(0.3)	1	0.69
Hepatic calcification	1	(0.3)	1	0.70	0			
Investigations	2	(0.7)	2	1.40	1	(0.3)	1	0.69
Electrocardiogram abnormal	1	(0.3)	1	0.70	0			
Heart rate increased	1	(0.3)	1	0.70	0			
White blood cell count decreased	0				1	(0.3)	1	0.69
Nervous system disorders	2	(0.7)	2	1.40	1	(0.3)	1	0.69
Loss of consciousness	1	(0.3)	1	0.70	1	(0.3)	1	0.69
Syncope	1	(0.3)	1	0.70	0			
Blood and lymphatic system disorders	0				1	(0.3)	1	0.69
Thrombocytopenia	0				1	(0.3)	1	0.69

N: Number of subjects with one or more events, %: Percentage of subjects with one or more events, E: Number of adverse events, R: Rate (number of adverse events per 100 PYO), PYO: Patient years of observation (1 PYO = 365.25 days). In-trial: Onset date on or after the day of randomisation and no later than the last subject-site contact or withdrawal/death date for subjects that withdraws/dies. MedDRA version 24.1. Events found via MedDRA queries. Daily basal insulin: IDeg.